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                                           ABSTRACT 
 
 
 
           Genomic Medicine in Primary Care:  Texas Physicians’ 
                  Adoption of an Innovation.  (December 2003) 
                                Sandra Gayle Suther, 
                    B.A., University of Texas at San Antonio; 
                     M.A., University of Texas at San Antonio 
              Chair of Advisory Committee:  Dr. Patricia Goodson 
 
 
New applications of genomic medicine stemming from the Human Genome 
Project are predicted to become routine components of primary care.  Primary care 
physicians (PCPs) will increasingly become responsible for screening patients for 
inherited diseases, recommending genetic testing, and making referrals to genetic 
services. Clinical applications of genomic medicine will occur at a variable pace.  
Characteristics of an innovation such as genomic medicine are strong indicators of its 
potential for adoption.  The purpose of this study is to assess whether (and to what extent) 
physicians’ perceptions of genomic medicine as an innovation influence their likelihood 
of adopting this innovation into primary care.   
The study’s sample consists of 400 primary care physicians in Texas and employs 
a survey design.  Based on Rogers’ Diffusion of Innovations Theory, the perceived 
characteristics of genomic medicine – Relative Advantage, Compatibility, Complexity, 
Trialability, and Observability – are the study’s independent/predictor variables.  
Likelihood of PCPs Adopting Genomic Medicine is the dependent variable.  The nature 
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of the social system (private or group practice) is examined as a possible moderator 
variable. 
 The study suggests that Texas PCPs who are likely to adopt genomic medicine 
strongly perceive its clinical uses (such as genetic testing for carrier status or 
susceptibility to common diseases, testing an embryo for genetic disorders before it is 
implanted, and supplementing a family history) to be highly advantageous.  For half of 
the PCPs, genetic services such as genetic counseling and genetic testing are not 
compatible with current practice.  Perceived complexity of the innovation is the strongest 
predictor of likelihood of PCPs adopting genomic medicine.  Many PCPs find it difficult 
to stay updated on genomic medicine and locate genetic services. Although Texas PCPs 
feel genomic medicine can be gradually incorporated into primary care practice, most are 
not presently observing their colleagues adopting genomic medicine or assisting their 
patients to make decisions regarding genetic services. 
 Future efforts to advance the use of genomic medicine in primary care will 
require more emphasis on genetics in medical school curriculum and continuing 
education programs.  Links with specialists trained in genetic counseling and health 
education will be essential to translate relevant information to patients and families. 
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CHAPTER I 
INTRODUCTION 
 
Knowledge, resources, and technologies stemming from the Human Genome 
Project have advanced understanding of the potential contributions of genes to human 
health.  With developments and new applications of such knowledge and technologies to 
the medical industry, the field of genomic medicine has been born.1
Genomic medicine will increasingly be used to address common conditions 
known to have significant genetic components.  Early intervention might be able to 
prevent some diseases such as hypertension, obesity, diabetes and cancer, while pre-
conception counseling can be appropriate for diseases that are lethal, severely disabling, 
or untreatable.2  Knowledge of the risk of a particular disorder will be useful for people 
who need to avoid the environmental triggers that convert gene susceptibility into 
disease.  Another prospect of genomics, the field of pharmacogenomics, has the potential 
to predict which medications will be most effective for specific patients.3  
Some health professionals dispute the claims that genomic medicine will 
revolutionize clinical practice and public health.4  For these professionals, medical 
genetics is still considered the province of specialists who spend their time evaluating 
unusual cases of Mendelian disorders, birth defect syndromes, or chromosomal 
anomalies.  However, according to Francis S. Collins, M.D., Ph.D., director of the  
 
________________________ 
     This dissertation follows the format of Genetics in Medicine. 
 
 2
National Human Genome Research Institute (NHGRI), “That is all about to 
change.”5(p540)  The next decade will see genetics spreading rapidly beyond the confines 
of specialist centers into primary care.3  While many primary care providers already  
incorporate genetic screening into their routine services, the demands on family 
physicians will increase substantially as new genetic tests and treatments become a 
routine component of medical care and prevention.6  Within this scenario, “medicine will 
no longer be for the sick.”7(p123)   Comprehensive genomics-based health care will be 
standard preventive medicine. 
Becoming familiar and staying updated with an ever-increasing number of genetic 
technologies will be a fundamental challenge for primary care because, as Williams 8 
points out, most primary care physicians (PCPs) have only received an introductory 
genetics course in medical school.  Most may not have the experience, training, or time to 
adequately order and interpret the results of complex genetic tests. 
Adoption of a medical innovation (new ideas or technology) often involves 
perceptions that a new intervention will benefit a patient or a population.9   For many 
primary care physicians, medical progress through new genetic technology has stimulated 
deep-seated anxieties concerning the sanctity of life.  Potential threats to the rights of the 
embryos, fetuses, women and the disabled have become just a few of the major 
concerns.10  
Primary care physicians are predicted to become genetics gatekeepers, “opening 
the gate” for patients by screening them for inherited diseases, recommending genetic 
testing, and making referrals to genetic service providers. However, clinical applications 
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of genomic medicine will occur at a variable pace for different disorders and in different 
areas of primary care.   
 
Purpose 
 The purpose of this study is to assess whether (and to what extent) physicians’ 
perceptions of genomic medicine as an innovation influence their likelihood of adopting 
this innovation into primary care.  The likelihood of adopting genomic medicine into 
primary care is this study’s dependent variable.  Physicians’ perceptions of specific 
attributes of genomic medicine are the predictor/independent variables.  As both 
likelihood of adopting genomic medicine and perceptions of genomic medicine as an 
innovation can vary according to the social/professional system physicians are engaged 
in, characteristics of their practice (i.e., whether they are involved in private or group 
practice) will be examined as having a potential moderating effect upon the dependent 
and predictor variables.    
 
 
Theoretical Framework 
This study is based on Everett M. Roger’s11 Diffusion of Innovations Theory.  
The theory defines innovation as an idea, practice, or object that is perceived as new by 
members of a social system.  The members of a social system may be individuals, 
informal groups, or organizations.  The innovation in this study is genomic medicine and 
the social system is the formal structure (private or group practice) within which the 
physicians practice.  According to Rogers,11 the composition of a system will influence 
the behavior of the members of the system.  Rogers defines diffusion as “the process by 
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which an innovation is communicated through certain channels over time among the 
members of a social system”11(p5)  For the purpose of this study, diffusion refers to the 
adoption of genomic medicine-related services into primary care practice.   
According to Rogers,11 there are five characteristics of an innovation that 
influence the rate of its adoption.  These are the relative advantage of the innovation, its 
compatibility, complexity, trialability, and observability.  Primary Care Physicians’ 
perceptions of these characteristics of genomic medicine will be measured in this study 
(see conceptual and operational definitions for each of these in the section describing the 
study’s variables, below).  The nature of the social system will be examined as a 
moderator variable, as it relates to the likelihood of primary care physicians adopting 
genomic medicine into their practice.     
 
Variables 
 Based on the Diffusion of Innovations Theory, the proposed model in Figure 1 
represents the relationship between primary care physicians’ perceived characteristics of 
genomic medicine and the likelihood of adopting this innovation.  Relative advantage, 
compatibility, complexity, trialability, and observability are the model’s predictor 
variables.  Likelihood of PCPs adopting genomic medicine is the dependent variable.  
The nature of the social system is shown in the model as a moderator variable. 
 
 
  
                                                   Perceived Characteristics of Genomic Medicine 
                                                                     Expectations/Expectancies 
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Relative Advantage
Complexity 
Trialability 
Observability 
 
Compatibility
Likelihood of 
PCPs Adopting 
Genomic Medicine
Professional 
beliefs 
Personal values 
and beliefs 
Current medical 
 practices 
Nature of Social System (moderator)  
 
Figure 1  Model to Assess Likelihood of PCPs Adopting Genomic Medicine 
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Dependent Variable 
 The dependent variable that will be measured in this study is, “Likelihood of 
Primary Care Physicians Adopting Genomic Medicine.”  Conceptually this variable is 
defined as the likelihood that primary care physicians will incorporate new 
developments in genetic technology into their practice.  Genetic technology includes 
genetic testing, genetic therapies, genetic consultations, and pre-conception counseling. 
 The dependent variable will be continuous.   It will be measured by adding the 
respondents’ scores from five items that question primary care physicians’ likelihood of 
1) ordering a carrier test for an autosomal recessive disorder, 2) ordering a 
preimplantation diagnosis on an embryo to check for genetic disease, 3) ordering a 
predictive test for a patient to check for risk of disease, 4) providing pre-conception 
counseling, and 5) referring a patient for a genetic consultation.  The items used a 5 
point likely-not likely Likert scale, for response. A lower score indicates a higher 
likelihood of adopting the innovation of genomic medicine.   
 
Independent/Predictor Variables 
 For the purpose of this study, the construct “perceptions” is being understood as 
“attitudes.”  Operationally, attitudes are usually measured through two dimensions:  
beliefs (outcome expectations) and values (outcome expectancies).12, 13  Expectation and 
expectancy questions were asked for each of the characteristics of the innovation of 
genomic medicine:  relative advantage, compatibility, complexity, trialability, and 
observability.  Multiplying each expectation and corresponding expectancy scores and 
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summing these products will compute respondents’ “perception” scores for each of the 
characteristics. 
“Relative advantage” is an important characteristic of the innovation that can 
influence its adoption.  The degree to which an innovation is perceived as better than the 
idea it supersedes is considered a relative advantage.11  If a physician perceives 
components of genomic medicine to have an advantage over what is being presently 
practiced, adoption will be more likely.  For example, he/she may believe one of the 
advantages of genomic medicine is, “to diagnose a genetic condition in an embryo 
before it is implanted instead of waiting and doing an ultrasound later in the pregnancy.”  
In this study, relative advantage is measured with 4 expectation items, using a 5 point 
agree-disagree Likert scale and 4 expectancy items (How important is it to you that…?), 
using a 5 point important-not important Likert scale, for response.  A lower score for this 
scale indicates a higher perception of the relative advantage of genomic medicine.   
 “Compatibility” indicates the degree to which the innovation is consistent with 
existing values, beliefs, and present practices of potential adopters.  Compatibility, in 
this study, is being proposed as a latent variable measured by 3 indicators:  
Compatibility of genomic medicine with primary care physicians’ professional beliefs, 
compatibility with current medical practices, and with their personal values and beliefs.  
The more genomic medicine can integrate and coexist with primary care physicians’ 
present technology and with their professional and personal beliefs, the greater its 
prospects for adoption and diffusion.  An example of a compatibility item in this study 
for the variable compatible with “professional beliefs” is, “Termination of pregnancy 
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when there is a substantial risk that if a child were born it would suffer from a serious 
mental or physical abnormality is consistent with my professional standards.”  
The indicators “professional beliefs” and “personal values and beliefs” are each 
measured with 2 items for expectations, using a 5 point agree-disagree Likert scale and 1 
item for expectancy, using a 5 point important-not important Likert scale.  A lower score 
on these two scales indicate a higher perception of the compatibility of genomic 
medicine with the professional beliefs and the personal beliefs and values of the primary 
care physician.  The compatibility with “current medical practices” indicator is measured 
with 3 expectation items, using a 5 point agree-disagree Likert scale and 1 expectancy 
item, using a 5 point important-not important Likert scale, for response. A lower score 
for this scale indicates a higher perception of the compatibility of genomic medicine 
with the primary care physicians’ current medical practice.   
A third construct measured in this study is primary care physicians’ (PCPs) 
perception of genomic medicine’s “complexity” or the extent to which the innovation is 
perceived as difficult to understand and use.  Genomic medicine will most likely require 
additional training in order for many PCPs to incorporate this innovation into practice.  
Available genetic resources will also be a necessity.  An example of a question to assess 
perceived complexity in this study is, “How easy or difficult is it for you to locate 
available genetic services?”   A perception of complexity is measured with 2 items for 
expectations and 2 items for expectancies, using a 5 point agree-disagree and easy-
difficult Likert scale, for response. A higher score for this scale signifies a perception of 
genomic medicine as highly complex.   
 
 9
“Trialability” is a characteristic of an innovation that refers to adopters’ ability to 
try it out on a limited basis without total commitment and with minimal investment.  
Trying out or gradually incorporating genomic medicine into primary care practice 
allows potential adopters to reduce uncertainty about its risks and benefits.  Many 
primary care physicians may feel genetic technologies cannot be incorporated on a trial 
basis.  In this study respondents were asked, “How important is it for you to incorporate 
technologies that you have tried first?”  A perception of trialability is measured with 2 
items for expectations and 2 items for expectancies, using a 5 point agree-disagree, 
important-not important Likert scale, for response.  A lower score on this scale indicates 
a higher perception that genomic medicine can be incorporated on a trial basis.   
  A related diffusion construct, “observability,” is a characteristic of the 
innovation that refers to adopters being able to observe how an innovation works by 
watching someone else use it and acknowledge that it is beneficial.  The more obvious 
the evidence or the more visible the positive results, the more likely it will be adopted by 
new users.  As more primary care physicians are observed ordering genetic tests and 
referring patients to genetic specialists with positive results, the sooner other primary 
care physicians will adopt this innovation.  Respondents in this study were asked if they 
agreed or disagreed with statements such as: “Most of my colleagues are assisting 
patients to make decisions regarding genetic services.”  Two expectation items and two 
expectancy items were used to measure observability, using a 5 point agree-disagree, 
important-not important Likert scale for response.  A lower score for this scale indicates 
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a higher perception that colleagues of the respondents are adopting genomic medicine 
into their practice. 
 
Moderator Variables 
Norms, roles, and social networks are very important to the diffusion of an 
innovation.  Diffusion theory proposes that the social networks or social systems through 
which innovations spread help govern the pace and extent of diffusion.  According to 
Cain and Mittmann,14 studies in the 1960’s of physicians prescribing tetracycline 
demonstrated that doctors with more extensive social networks—those on hospital staffs, 
those in group practices, and those who consulted with other physicians—adopted the 
drug faster than doctors who were more socially isolated.  Whether the respondents are 
involved in private or group practice was examined in this study as having a possible 
moderator effect upon the dependent and predictor variables.   
 
Demographic Variables 
Age, gender, ethnicity, year of graduation, medical school, specialty, and practice 
characteristics will be used as control variables in multivariate analysis and examined for 
possible differences or relationships between and among groups. 
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Definitions 
Primary care physician (PCP) will be defined in this study as a medical 
practitioner who serves as a patient’s first point of contact into the health care system 
and takes continuing responsibility for providing the patient’s care.15 Primary care 
encompasses internal medicine, pediatrics, obstetrics, gynecology, family practice, and 
general practice.  Primary care includes health promotion, disease prevention, patient 
counseling and education, diagnosis and treatment of acute and chronic illnesses in a 
variety of health care settings.15   
Private practice will be defined as medicine practiced independently by a 
physician.  Group practice will be defined in this study as medicine practiced by a group 
of associated physicians16  
 Genomic medicine is defined as the use of DNA testing to enhance the quality of 
medical care including pre-symptomatic identification of predisposition to a disease, 
preventive intervention, selection of pharmacotherapy, and individual design of medical 
care based on genetic makeup.17  Genomics has also been defined as the study of “all the 
functions and interactions of all the genes in the genome” including their interactions 
with environmental factors.18(p1513)   Guttmacher & Collins 18, distinguish between 
“genetics” and “genomics.”  “Genetics is the study of single genes and their effects.  
Genomics, a term coined only 15 years ago, is the study not just of single genes, but of 
the functions and interactions of all the genes in the genome.”18(1512) The human genome 
is the full collection of genetic material in a human cell .19  A glossary of genetic terms 
used in this manuscript is included in Appendix A. 
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CHAPTER II 
 
BACKGROUND/LITERATURE REVIEW 
 
 
 This chapter is divided into three sections.  The first section presents the 
history and background of the Human Genome Project.  Finished ahead of schedule and 
under budget, this project is responsible for the evolution of genetics into genomic 
medicine.  As providing genomic information and advice will become the domain of 
primary health care providers,20 the second section of this literature review examines the 
role of primary care physicians and the barriers they face in the new genomic revolution.  
The third section illustrates the Diffusion of Innovations theory and describes some of its 
uses in the field of health care. 
 
Genetics to Genomics 
 
In the early 1950s, evidence from two experiments provided clues to the structure 
of deoxyribonucleic acid (DNA).  Chemical analysis by Austrian-American biochemist 
Erwin Chargaff revealed the base components and proportions of DNA.21   Next, English 
physicist Maurice Wilkins and English chemist Rosalind Franklin observed the regularly 
repeating structure of building blocks of DNA with the help of a newly developed 
imaging technique called x-ray crystallography.  The images showed DNA was helical 
or shaped like a spiral (Figure 2). 21,22
 In 1953, American biochemists James Watson and Francis Crick worked 
together in England to build a three-dimensional replica of the DNA molecule using 
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ball-and-stick models (Figure 3).21  Watson and Crick’s proposed model showed how the 
DNA’s two chains wound around each other, with paired bases inside.  The two 
scientists suggested that DNA copied itself and enabled genetic information to flow from 
one generation to the next. 22  On April 25, 1953 in a one page scientific publication in 
the journal “Nature”, Watson and Crick stated with simplicity, “It has not escaped our 
notice that the specific pairing we have postulated immediately suggests a possible 
copying mechanism for the genetic material.”23, (p737)  
 
 
 
Figure 2  The X-ray Diffraction Pattern of DNA, Taken by Rosalind Franklin*
 
 
Although Watson and Crick’s contributions still capture much of the public 
awareness, their breakthrough was one of many in an ongoing series of insights into the 
                                                 
* Courtesy of the Cold Spring Harbor Laboratory Archives.  2003. 
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fundamental design of life.24  Gregor Mendel, a German botanist and Augustinian monk, 
formulated the basic laws that govern inherited characteristics less than a century earlier, 
and the 1940s saw the discovery of chromosomes as the sites that contain the genes.21   
Rosalind Franklin was a young woman when she contributed the x-ray diffraction data 
that would prove so pivotal to the elucidation of the structure of DNA.  However, she 
did not share the Nobel Prize with Watson, Crick, and Wilkins because she died from 
ovarian cancer before the prize was awarded.  It is speculated that she developed the 
cancer from her years of working with radioactive chemicals.21
 
 
 
 
Figure 3  James Watson and Francis Crick with Their DNA Model†
The double helix discovered by Franklin and confirmed by Watson and Crick set 
the stage for sequencing the entire human genome “and turned genetics, the study of 
                                                 
† Image reprinted with permission.  Copyright © 2002. Photo Researchers, Inc.     
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single genes, into genomics, the study of the interaction of all genes with one another 
and with their environments.” 25 (p949)   
Increasing evidence of the importance of genetics in almost all diseases resulted 
in the development of the Human Genome Project in the mid-1980s.26   The first serious 
discussion of sequencing the human genome was lead by Robert Sinsheimer, then 
chancellor of the University of California at Santa Cruz.27  In 1986, Charles DeLisi of 
the U.S. Department of Energy (DOE) decided to begin funding research into genome 
mapping and sequencing.27  In 1988, a special committee of the U.S. National Research 
Council of the U.S. National Academy of Sciences recommended the initiation of the 
Human Genome Project, calling for a 15-year project with funding of about $200 million 
a year.27  The same year the National Institutes of Health (NIH), led by James Watson, 
joined the effort with the Department of Energy. When Watson departed in 1992, 
Francis Collins assumed the lead role at the NIH in 1993, and Michael Morgan at The 
Wellcome Trust (Great Britain) in 1992.  Aristides Patrinos took the lead of the 
sequencing effort at the DOE in 1995.  Recalling those early years, Collins, Morgan, and 
Patrinos27 stated, 
The next several years were turbulent, as we learned ‘on the job’, made lots of 
mistakes, and experienced more than a few moments of great anxiety that the 
whole enterprise might fail; but ultimately, we watched the creativity, talent, and 
dedication of those involved in the public genome project surmount every 
obstacle and beat every deadline. We also realized that what we were learning 
had implications that extended beyond the human sequencing effort itself to the 
management of large-scale biology in general. (p286)
 
 February 28, 2003 was the 50th anniversary of the discovery of the three-
dimensional structure of DNA by James Watson and Francis Crick.  In April 2003, a  
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“high-quality comprehensive sequence of the human genome” was completed 2 years 
ahead of time.28 (p835)  More than 20 different major sequencing centers in six countries - 
China, France, Germany, Great Britain, Japan, and the United States - and hundreds of 
scientists participated in the project.28 
 The field of medical genetics traditionally covered a relatively limited range of 
single-gene disorders such as the ones listed in Table 1.  Now it is known that of the 
30,000 estimated chromosomal genes, about 1,000 carry disease-causing mutations.  
Moreover, Mendelian diseases that took large research teams years to identify in the past 
can now be identified in just a few weeks.28  The Human Genome Project has identified 
hundreds of genes for an equal number of diseases such as cystic fibrosis, Huntington 
disease, breast and colon cancer, Retinoblastoma, Alzheimer’s disease, and 
hemochromatosis. Specific chromosomal regions have even been identified for traits 
such as obesity, depression, violence, and homosexuality.29  
The sequencing of the human genome and other recent achievements in 
genomics have provided an opportunity to advance our understanding of the role of  
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Table 1 
Some of the Most Common Single-Gene Disorders30,31, ,32‡
 
Condition 
 
 
Hypercholesterolemia 
 
A dominantly inherited genetic condition that results in elevated LDL 
(low-density lipoprotein) cholesterol levels beginning at birth and 
resulting in myocardial infarctions (heart attacks) at an early age. 
 
Diabetes, type I 
 
Several different genes may act together along with other 
environmental and lifestyle factors to trigger diabetes. In type I 
diabetes, the beta cells of the pancreas produce little or no insulin, the 
hormone that allows glucose to enter body cells. Once glucose enters a 
cell, it is used as fuel.  Without adequate insulin, glucose builds up in 
the bloodstream instead of going into the cells.  The body is unable to 
use the high levels of glucose for energy.  
 
Breast and ovarian cancer 
 
Mutations in the BRCA1 and BRCA2 genes are associated with an 
increased risk of breast and ovarian cancer.  
 
Down Syndrome A chromosomal condition causing mental retardation and characteristic 
facial features. Other complications may include congenital heart 
disease and childhood leukemia. 
 
Fragile X Mental Retardation 
 
An X-linked syndrome that is the most common genetically-inherited 
form of mental retardation. Some children appear normal in infancy but 
develop intellectual disability and typical physical characteristics such 
as prominent ears during their lifetime. Mental impairment may range 
from mild to severe. 
  
Sickle Cell Anemia An autosomal recessive condition causing vasoocclusive events, 
resulting in pain, cerebrovascular complication, and renal dysfunction. 
  
Cystic Fibrosis An autosomal recessive condition causing progressive lung disease.  
Most affected patients also have pancreatic insufficiency. 
  
Duchenne Muscular Dystrophy An X-linked recessive condition causing progressive skeletal-muscle 
weakness and cardiomyopathy. Affected children are typically 
wheelchair-bound by the age of 12 years. Death is usually due to 
cardiomyopathy or respiratory failure. 
  
Hemophilia A A hereditary blood coagulation disorder caused by a deficient activity 
of plasma protein factor VIII, which affects the clotting property of 
blood. 
  
Marfan Syndrome An inherited collagen-based disorder characterized by long, thin arms, 
legs, and digits of the hands and feet. Ocular problems occur, and aortic 
heart disease most frequently is the cause of premature death. 
                                                 
‡ Adapted with permission from: Burke W. Genomic medicine: Genetic testing. N Engl J Med. 
2002;347(21):1867-1875.  Copyright © 2002.  Massachusetts Medical Society.  All rights reserved. 
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genetic factors in human health and disease, to allow more accurate explanation of non-
genetic factors involved, and to apply this insight to the prevention, diagnosis and 
treatment of disease.28    
Collins and colleagues28 identified 3 large-scale strategies that will utilize the 
information from the Human Genome project to advance improvements in human 
health: 
• Identification of genes and pathways with a role in health and disease, 
and determination of how they interact with environmental factors. 
 
• Development, evaluation and application of genome-based diagnostic 
methods for the prediction of susceptibility to disease, the prediction of 
drug response, the early detection of illness and the accurate molecular 
classification of disease. 
 
• Development and deployment of methods that catalyze the translation of 
genomic information into therapeutic advances. 
 
Improvements in diagnostics and treatments resulting from these strategies are 
anticipated to change the future of medicine and will become the standard of care in 
primary practice. 
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Genomic Medicine in the Primary Care Practice 
 
Primary care physicians (PCPs) are increasingly becoming the main point of 
entry for genetic services in many countries.33 Many patients feel more comfortable 
revealing family history of unusual disease to their primary care practitioner rather than 
to an unfamiliar genetic specialist.  This puts the PCP in a good position to offer prenatal 
counseling to his/her patients as well as advice about genetic procedures and available 
options.33 However, most of the research examining PCPs’ adoption of genetic medicine 
has uncovered four major barriers to the provision of genetic services:  lack of 
knowledge, lack of referral skills, skepticism about the impact of genetics on primary 
care practice, and lack of information about available resources.  
 
Lack of Knowledge 
Kolb and colleagues34 found the primary reason for underutilization of genetic 
services by primary care providers in a Texas community was lack of adequate genetics 
information.  After administering a 16-hour basic genetic educational program 
supplemented by a 150-page course manual, several pamphlets on specific genetic 
conditions and a videotape that was developed by the Texas Department of Health, there 
was an increase in knowledge and change in attitudes of the primary care providers 
towards genetic services. 
Focus groups with 26 general practitioners concluded that lack of genetic 
knowledge and referral skills were also a barrier to providing genetic services in 
Britain.35  Although the physicians considered genetics as important and increasingly 
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relevant for primary care, they felt the added responsibilities of genetics will require new 
knowledge and skills beyond what they are currently practicing. 
In 1933 M.T. Macklin36 declared, “Medical genetics should be taught in medical 
school, in the final year of medicine…Such a course…would be of value from four 
distinct points of view:  diagnosis, therapeutics, prevention, and public health.” (p 16)  
Today the underemphasis on genetics in medical school is still being partially blamed for 
the knowledge gap.  “As practicing clinicians, we are left to delve into the black box of 
genetics with our limited backgrounds and often with even less appreciation for the 
practical relevance of genetics to our daily practice.” 37 (p6)  Dumont-Driscoll37 feels the 
“scant 2 weeks” allocated in the medical curriculum has created an enormous need for 
physicians to seek additional education in a previously underemphasized area of medical 
education. (p6)  
Williams8 agrees that medical schools offering only an introductory genetics 
course during the first or second year compound PCPs’ lack of genetic knowledge.  This 
lack of training leaves PCPs undereducated in a field that is expanding so quickly that 
even genetic practitioners are hard-pressed to keep up.  Medical schools have been slow 
to recognize the profound implications of genomics for clinical medicine.25   “There is 
inadequate time in the crowded curriculum and insufficient faculty to teach the new 
science at the necessary cellular, clinical, epidemiological and ethical levels.” 25 (p949)    
Aggravating this knowledge gap will be those already in practice who will need 
continuing education in order to counsel patients regarding genetic testing and to help 
patients understand their specific health risks.25    
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In contrast, Korf 38 contends that an extensive knowledge of the science of 
genetics will not be necessary for PCPs to use genomic medicine in future practice.  The 
author claims genetics can be used in day-to-day practice by employing only important 
concepts and skills of basic genetics and by using them wisely.  As far as medical 
curriculum, education goals of students are not all the same.  Some may be preparing for 
primary care while others for specialty practice, research or public health.38   In 
agreement with Korf, Dumont-Driscoll37 stresses, “The general concepts are critical, but 
the knowledge of their intricacies, although intellectually exciting, are no more 
necessary than our knowledge of computer hardware to successfully write a memo or 
significant expertise in technology to use our household electrical equipment.”(p7)  It will 
be a challenge to genetics educators to focus on material relevant to primary care 
practice as well as to persuade many physicians that they need only to focus on what is 
important.   
Many PCPs will want to have a hand in determining the specific content of what 
they are taught about genetics.20  However, with the rapid pace of new information, too 
narrow a focus will fall short of what PCPs are going to need to practice genomic 
medicine.  A workforce in primary-level genetic services will require PCPs to “think 
genetically” with every patient.39   While the PCP already evaluates each individual in 
the context of his or her family and community,39 genomic medicine will move  
physicians away from viewing the human body as a machine towards realizing each 
individual’s genome may respond differently to his or her environment.37  
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Skepticism about the Impact of Genomic Medicine 
Skepticism about the impact of genetic discoveries on primary care practice 
could be a barrier to providing genetic services.40  This doubt may cause genetic training 
to be a low priority for many primary care physicians.41,42  Hayflick and colleagues42 
reported six percent of physicians in their study (examining primary care physicians’ 
perceptions of genetic services) felt no need to include these additional services in their 
practice.  Lack of effective screening technologies and therapies to reduce risk or 
prevent disease caused practitioners in Kumer and Gantley’s35 study to believe genetic 
advances had little relevance for their practice. 
Rapidly evolving advances in genetic testing, pharmacogenetics, and gene based 
therapies have important implications for primary care physicians because they are 
mainly responsible for initial assessment of medical problems, disease prevention and 
long-term care of their patients.43 However, the need for the development of additional 
genetic curriculum and continuing medical education might not seem urgent for the 
many PCPs who are skeptical about the relevance of genetics.43  
A 1998 American Medical Association’s survey found that 71% of patients with 
a possible family history of genetic disease would rely on their primary care physician 
for advice about genetic services.44  Yet, thirty-nine percent of the PCPs responding to an 
American College of Obstetrics and Gynecology survey rated genetic issues as last 
among their priorities and two-thirds were not confident of their knowledge of 
genetics.45    
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Benítez-Bribiesca29 complained that most of the success of genomic medicine 
has been with rare diseases that comprise only 5% of all our pathologies.  Genes related 
to the most common diseases such as cancer, infections, arteriosclerosis, and mental 
disorders have yet to be conquered.  Even though genetic discoveries have led to 
noteworthy advances in the ability to better understand and diagnose many rare genetic 
disorders, the lack of effective interventions suggests that genetic technologies will be 
slow to be adopted into primary care medicine.46  Genetic screening measures 
historically have focused on reproductive issues, such as preconception screening for 
those at risk of being carriers of autosomal recessive diseases like Tay-Sachs disease and 
cystic fibrosis or prenatal diagnosis such as Down Syndrome.  Newborn screening is 
generally mandated by state or federal government health policies and occurs outside the 
physician’s responsibility.47    Many PCPs do not yet feel much need to prepare for the 
kind of practice in which predispositional genetic testing for susceptibility to common 
adult disorders may become routine. 
Pinksy and colleagues47 complained,  
The impending ‘genetic revolution’ has been so over promoted by members of 
the scientific, corporate, medical, and political communities that it is tempting to 
dismiss the role of genetics in primary care entirely.”(p47)  
 
  Chanock & Wacholder 48 confirmed two major gaps in the implementation of 
genomic medicine: “1) the chasm between existing genetic information and its clinical 
utility and 2) the translation of collected data into effective clinical practice.” (p268)  They 
questioned whether more data will mean more useful information for those health care 
practitioners who do not even know which genetic tests are available much less how to 
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interpret the results.  Lack of a basic understanding of these expensive genetic tests will 
increase the chance that test results will be misinterpreted.49   In addition to interpreting 
the tests, the patients will expect to know why a test is performed, what the 
consequences are, and its implication for clinical care.48  
 
Lack of Referral Skills/ Information about Available Resources 
There has been criticism that physicians are fed a rich daily diet of gene 
discovery and ethical dilemmas yet they lack basic information on the uses of genetic 
testing and the tenets of genetic counseling that will allow them to incorporate these 
concepts into their practice.47  Primary care physicians (PCPs) may be more comfortable 
referring patients to a genetic clinic or specialist for testing and counseling than actually 
ordering the test themselves because they are unable to interpret the test results for their 
patients.  The necessity to explain the medical and behavioral implications of a genetic 
test in the primary care setting will also require additional training. 
Recognition by the primary care physician of the signs that indicate the need for 
a genetics referral is an essential part of providing the most accurate diagnosis, 
information about the risk of recurrence, and medical management for the patient and 
family.50  Many PCPs are unfamiliar with the role of clinical geneticists (MDs primarily 
involved with diagnosis of genetic disorders and counseling of patients and their 
families).36  The assumption is that a geneticist is a specialist working in research.  
Curtis36 explains that misunderstandings of genetics and its applications are common and 
can differ depending on the background of the people involved.  For example, molecular 
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geneticists that investigate cystic fibrosis may not be familiar with the role of bacterial 
genetics that investigates the resistance to antibiotics. 
A genetics consultation is often much more time-consuming than most medical 
visits.19 Obtaining a more extensive family history is an essential start in the assessment 
and management of genetic disorders.  According to Elsas and Trepanier,51 a complete 
family history includes collecting information on parents, siblings, daughters, sons, 
aunts, uncles, and grandparents, which is then formatted into a genetic pedigree.  The 
history should also include information about all types of cancer in both the paternal and 
maternal lineages as well as ascertaining ancestry.  
Another limitation to the typical “gatekeeper” system is not only that “primary 
care physicians must recognize the value of genetic intervention to write a referral, but 
the medical management department of the MCO [managed care organization] must 
agree and authorize the referral.” 8 (p432)  For many PCPs and consumers, obtaining 
genetic subspecialty appointments is already difficult.  Patients and consumers residing 
in smaller cities or rural areas have limited access to genetic specialists who are typically 
concentrated in academic medical centers in major cities.52 
The increasing demand for genetic services will stretch the already limited 
number of specialists making it even more difficult for both urban and rural community 
physicians to consult with and refer patients to the appropriate specialist.37   In an 
estimate of certified genetic specialists in the USA, Evans & Britt44 found that there are 
approximately 3,000 physicians, nurses and counselors (not all of whom are engaged in 
clinical practice) serving a population of approximately 270 million people.  Yet, 
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Pletcher and colleague’s53 study confirmed that reimbursement for geneticists and 
genetic counselors is just as poor now as it was 14 years ago despite the substantial 
professional time commitment involved providing genetic services.   
Researchers question whether there is a need to train more clinical geneticists to 
provide for the increasing need for comprehensive genetic care or a need for geneticists 
to educate and train PCPs to incorporate genetics into their practice.53  Despite 
reluctance by primary care practitioners to adopt these new responsibilities, “all 
branches of medicine, especially primary care, will be required to advise patients about 
genetic issues” 54(p1030) As argued previously, clinical genetics departments will be 
unable to cope with the rise in demand of genetic referrals and consultations, given their 
existing workforce.54    
Many primary care practitioners lack information about genetic services and 
options available to patients.55 Not knowing which choices are available decreases their 
confidence to assess, counsel and refer patients to services offered by genetic clinics.  
Watson and colleagues 55 sought to determine if provision of printed materials alone was 
effective to disseminate new knowledge and implement guidelines successfully.  One 
group of practitioners in this study was issued a tailored information pack while another 
group received an education session supplemented by the information pack.  The second 
group fared no better in appropriate referral decisions than the group with the 
information pack alone.  However, both groups fared better than the control group that 
did not receive either aid. 
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The trigger for a “need to know” more about clinical genetics has not really been 
elicited yet for most PCPs.  An underlying cause for this possible denial is not knowing 
where or how to access the appropriate genetic services.37  Lack of use of the services 
that are available may be tied to the PCP’s skepticism of the value of genomic medicine.  
But Dumont-Driscoll37 contends, “Believing that outcomes are not affected by the 
genetic information provided is inaccurate, inappropriately judgmental, and potentially a 
high risk for the patient and physician.” (p9)   
 
Ethical, Social, and Legal Issues 
Barriers to implementation of genetic technology or skepticism about the clinical 
validity and utility of genomic medicine will no doubt hinder PCPs incorporating 
genomic medicine.  Additionally, there will be many ethical, social, and legal issues that 
will need to be addressed.  Apprehension about possible privacy breaches, stigmatization 
and discrimination may cause physicians and consumers alike to avoid genetic related 
services as well as participation in research.56  
Discussions regarding the implications or applications of genomic medicine have 
not included the perspectives of the general population, especially the voices of racial or 
ethnic groups.57 Historically in the United States, as well as in Europe, explanatory 
causes of particular diseases or social problems have been viewed as arising out of 
genetic material.  For example, the eugenics movement in the United States in the early 
1900s proposed solutions to social problems such as poverty by encouraging fertility 
among the upper and middle classes and discouraging childbearing among those from 
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lower socioeconomic groups.57   Another example is the period during which Nazi war 
criminals of the 1930s and 1940s singled out Jewish, gypsies, and homosexuals on the 
grounds that they were genetically inferior.57 
Pletcher and colleague’s53 survey data indicated that Hispanic and African 
American practitioners are extremely underrepresented as geneticists.  The authors felt 
the ethnocultural changes in the U.S. suggest a need for a more racially and ethnically 
diverse genetic workforce as well as multicultural training in genetic residency 
programs. 
Although it has been determined that there is no basis in the genetic code for 
race,58 physicians need to be aware of the availability of population-based genetic 
screening such as for Tay-Sachs disease in Ashkenazi Jewish individuals or hemoglobin 
disorders in those of African, Mediterranean, or Asian descent.38  As Lin-Fu and Lloyd-
Puryear59 stressed, this type of genetic screening and counseling is intended “to give the 
population at risk the information needed to make informed choices and prepare for the 
outcome of their decision.” (p284) 
Pre-conception screening or prenatal diagnosis is usually offered when there is a 
family history of genetic disorder or inherited chromosomal abnormality, when a couple  
already has an affected child, or if the parents are comparatively old.10  Prenatal 
diagnostics are performed during pregnancy.  The only options available following a 
prenatal diagnosis of an inherited disease are to give birth to an affected child, or to 
terminate the pregnancy.  An alternative to prenatal diagnosis, pre-implantation genetic 
diagnosis, is a much less intrusive and invasive procedure involving the selection and 
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implantation of healthy embryos rather than abortion of an affected fetus.45 Geller and 
colleagues60 found that primary care providers are much more likely than genetic 
specialists (~44% of PCPs vs. ~16% of medical geneticists) to express an opinion to the 
patient whether or not she should opt for prenatal diagnosis.   However, preimplantation 
diagnosis is rarely suggested to women as an alternative option to prenatal diagnosis by 
most physicians because it makes the decision-making process more complex when 
having “to differentiate the ‘acceptable’ from the ‘non-acceptable’ in terms of gender or 
other characteristics”  which may devalue genetic diversity.45(p754) 
Adams and Cain45 point out that the intent of both prenatal testing and pre-
implantation genetic diagnosis is eugenic in that it aims to reduce the number of people 
with genetic disorders through the rejection of characteristics that may not be in and of 
themselves fatal nor cause severe suffering in childhood.  In defense, Kitcher61 feels that 
it is with the best intentions that physicians or parents justify prenatal testing and 
termination of a pregnancy if it would prevent the birth of a child whose life would be 
brief and agonizing.  However, many PCPs as well as other groups worry that it would 
be very easy to move away from trying to avoid human suffering to attempting to 
implement full-blown eugenics. 
By the year 2010, it is expected that predictive genetic tests will be available for 
as many as a dozen common conditions, allowing individuals who wish to know this 
information to learn their individual susceptibilities and to take steps to reduce those 
risks for which interventions are or will be available.5  But access to expensive new 
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genetic tests will be difficult for primary care patients, especially for Medicaid recipients 
and the uninsured.45
The discovery of genetic predisposition to chronic and inherited disease has set 
up the potential for discrimination in everything from who is marriageable to who is 
insurable.  Stigmatizing groups that have been labeled high risk may not only result in 
their inability to obtain health insurance but also to obtain certain jobs.44  Patients who 
are eligible for health care services under Medicaid may not experience barriers to 
genetic services for financial reasons to the degree encountered by those who are 
employed in low paying jobs with little or no health care benefits or those with private 
insurance.  And if insurers are allowed to use genetic information in adjusting premiums, 
the burden of paying large if not impossible sums to obtain health care coverage will 
afflict numerous Americans who never thought of this as their problem.62   
According to Cunningham,62 when obtaining consent for any genetic tests, risks 
and benefits must be discussed, including the potential for false-positive and false-
negative test results and the potential effect of these findings on self-image, family 
relationships, employment, and insurance coverage, as well as the physical and 
emotional burden of the disorder.  As if this would not take up enough consultation time, 
the patient also needs to understand the difference between screening tests, which could 
place a person in a high-risk group, and diagnostic tests, which dictate treatments.62 
One of the most complex issues accompanying the evolution of genetic sciences 
relates to how the results of genetic tests are to be used.  Federal legislation has been 
proposed to define the rights of insurers and consumers; no significant efforts, however, 
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have been passed directly relating to this issue.1 Consumers believe that allowing 
insurers access to genetic information would violate rights of privacy, prevent patients 
from getting needed help, and lead to widespread discrimination against applicants.63  
However, Pokorski and colleagues64 make a good case that lack of data regarding the 
effectiveness of preventive treatment or interventions for patients with a genetic 
predisposition is consistent with other circumstances in which insurers feel compelled to 
deny coverage.  Insurance companies have a natural interest in this data because 
assessment of risk is an essential factor in profitability.64  
Another concern for PCPs is the psychological and emotional impact that 
positive test results can have on some patients.  Especially patients with a family history 
of a disorder such as Huntington’s Disease (also known as Huntington’s Chorea).10  
Affected individuals with this disorder undergo gradual neural degeneration until they 
die.  This lethal disorder is particularly tragic because it has such a late onset, typically at 
about age 40.  By that time, the affected individual may have produced a family.  Each 
child has a 50% probability of inheriting the disorder and transmitting it to his/her 
children.32  
In families with Huntington’s disease, individuals are often painfully aware of 
their risk, having lived for years with mixed hope and dread.  Many people desire 
genetic information, even after they are made to understand its impact.  In many cases, 
the family doctor is the most appropriate person to do the counseling because he/she 
knows the family and its attitudes and background better than an outside consultant.  
However, the PCP may have neither the genetic knowledge nor the time.  Moreover, 
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some cases may be so complex or require such specialized tests that the services of a 
professional genetic counselor are needed.  When the patient’s decision to undergo 
testing reflects a desire to move forward in some way, and to end a long-standing 
struggle with anxiety and uncertainty, having to disclose a positive test can be very 
emotional.10 
Evans and Britt44 brought up a potential budgetary conflict between two federal 
health efforts, the Human Genome Project and the Healthy People 2010.  The authors 
point out that the “massive wishlist” of the Healthy People 2010 revolves around low-
cost solutions to public health issues such as increasing women’s folic acid intake to 
prevent neural tube defects.  But nowhere in this lengthy document does it push for 
access by the general population of women to costly genetic innovations such as genetic 
screening for breast or ovarian cancer.44   Genetics plays a role in approximately half of 
the ten leading health indicators selected as public health issues in the Healthy People 
2010 document.65  Of the total 467 objectives, only one deals specifically with genetics 
(newborn screening).  
According to Grosse and Teutsch,66 advances in human genetics will require 
systematic assessments as to their rational translation into public health policy and 
practice.  They further explain that the prevention effectiveness of a public health 
strategy is decided based on whether it is considered more effective, less costly, and 
poses no risks of harm.  However, they found it to be more common that a public health 
strategy that is superior on one or more criteria usually ranks poorly on another. 
 
 33
Companies that hold patents for genetic tests in order to offer them for profit will 
no doubt keep the costs of these tests high. It was agreed that all the data produced from 
the Human Genome Project would be “freely available and in the public domain, in 
order to encourage research and development and to maximize its benefits to society.”67 
(p29)  Yet three million genome-related patent applications have already been filed.  
While it will take years to interpret much of the data detected by the Human Genome 
Project, especially with respect to common diseases, the physicians are concerned that 
commercial interests are already capitalizing on certain aspects of genomic medicine.  
To maximize revenues, many genetic centers and laboratories could deviate from 
nondirective counseling by prescribing unnecessary tests.60   
Primary care providers get to know their patients well from both the medical and 
personal perspective.  Because primary health care providers are often the first to be 
asked about hereditary disorders, he or she is in a unique position to direct the use of 
genetic technology for decision-making.  But physicians are trained primarily to treat 
disease once it occurs.68  Improved predictive capabilities provided by the Human 
Genome Project will benefit individualized risk assessment when relatively minor 
changes early in life may postpone or prevent the onset of disease.69   However, 
complexities such as updating genetic knowledge, allotting more time for genetic 
services, and addressing the ethical, social, and legal issues of genomic medicine may 
impede the adoption of this innovation into primary care. 
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The Diffusion of Innovations in Health Care 
 
 Everett Rogers defines diffusion as the process by which an innovation is 
communicated through certain channels over time among the members of a social 
system.11  There are four elements that are present in the diffusion of innovation process:  
the innovation, the communication channels, time, and the characteristics of the social 
system.   
The innovation is an idea, practice, or object that is perceived as new by an 
individual or other unit of adoption.  The characteristics of an innovation are strong 
indicators of the rate of diffusion and adoption.70 The characteristics are divided into five 
categories that affect the rate at which an innovation gets adopted.71 
Relative Advantage – Is the innovation perceived to be better than the status quo? 
Compatibility – How does the innovation fit with people’s past experiences and present 
needs?  Does it require a change in existing values? 
Complexity – How difficult is the innovation to understand and apply? 
Trialability – Can people “try out” the innovation first?  Or must they commit to it all at 
once? 
Observability – How visible are the results of using it?  If people adopt it, can the 
difference be recognized by others? 
The communication channel is the path of information flow between and among 
individuals – the means and medium of communication.  Mass media and interpersonal 
channels are two types of channels typically identified.70 New information related to 
health is diffused through professional peer-reviewed journals and face-to-face at 
 
 35
meetings.  On the surface, the limited channels of communication – journals, 
professional meetings – make it appear that the communication process would be easy. 
But the multiple layers of professional specialty groups within the health field, each with 
their own journals can actually slow down the diffusion process.72 
The concept of time in the diffusion process is noticeable in three distinct areas: 
the innovation-decision process or the course taken from initial awareness of the 
innovation to its full adoption, the innovativeness of the individual or other unit of 
adoption, and the rate of an innovation’s adoption within a system. 
A social system is defined as a set of interrelated units that are engaged in joint 
problem solving to accomplish a common goal.11  The social structure of a system is the 
hierarchical arrangement of its members.  The social systems in health and medicine are 
hierarchical.73  For example, medicine tends to have more political clout than does 
public health.  Also, more attention is drawn to research findings in medicine than in 
other health fields such as nursing, which is considered a lower-status field.72  The social 
system directs the path of diffusion and the behaviors of the system’s individual 
members dictate the rate and volume of its flow.70 
 
Brief History of the Diffusion of Innovations Theory 
The original diffusion research was done in 1903 by the French sociologist 
Gabriel Tarde.  Tarde plotted the original S-shaped diffusion curve where the rate of 
adoption increases slowly at first, then rises rapidly, and finally slows down and levels 
off (Figure 4).  In his Laws of Imitation, Gabriel Tarde argued that proximity led to 
imitation.73   In the 1920’s a group of British and German-Austrian anthropologists used 
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“diffusionism” to explain how social change in a given society was a result of the 
introduction of innovations from another society.11 (p41)   
 
SATURATION 
Adoption 
     Of 
Innovation
Take-Off  
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                               Figure 4   The Innovation Adoption Curve71 
 
Early applications of the Diffusion of Innovations theory involved research to 
understand how agricultural techniques were spread among farmers.73,74  In the 1940’s, 
two sociologists, Bryce Ryan and Neal Gross published a study of the diffusion of 
hybrid corn seed among Iowa farmers, renewing interest in the diffusion of innovation 
S-curve.  The rate of adoption curve was similar to the S-shaped diffusion curve graphed 
by Tarde.75  Ryan and Gross classified the segments of farmers in relation to the amount 
of time it took them to adopt the innovation.75  The five segments of farmers who 
adopted the hybrid corn seed, or adopter categories were: 1) innovators, 2) early 
adopters, 3) early majority, 4) late majority, and 5) laggards (Figure 5). 
           Time 
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Figure 5   Adopter Categories of Innovation S-Curve73 
 
In 1953, H.G. Barnett suggested that the likelihood of adoption of a new practice 
depends on the relative gain in satisfaction over current practices.73    In 1963, Katz, 
Levin and Hamilton defined diffusion as “a sociological process characterized as the 
acceptance over time of some specific idea or practice by individuals, groups, or other 
adopting units, linked to specific channels of communication, to social structure, and to a 
given system of values or culture.” 73 (p 166)  In 1983, Rogers11 proposed that innovations 
could be characterized by their relative advantage over alternative products or behaviors, 
their compatibility with existing values, their complexity, trialability and their 
observability. 
 
Diffusion of Innovations in Health Care 
Studies using the Diffusion of Innovations theory to examine the perceptions of 
primary care physicians toward the innovation of genomic medicine have not been 
published.  Therefore applications of Diffusion of Innovations theory to health care are 
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reviewed in this section.  In the field of health care, the theory has been used to study 
family planning behaviors, the use of medical tests and technologies, and the use of new 
pharmaceutical agents. 73,74   Interventions for smoking cessation, safe sexual practices, 
dissemination of community-based cholesterol and diabetes screening are just a few 
ways earlier applications of the Diffusion of Innovations theory have given way to its 
extensive adoption by health education and health promotion. 73,74  
Svenkerud and Singhal76 investigated the effectiveness of specific concepts from 
Diffusion of Innovations (DOI) in an effort to outreach culturally unique populations at 
high risk for HIV/AIDS in Bangkok, Thailand.  They found that only 2 concepts of DOI 
were utilized consistly by the HIV/AIDS programs – communication channels and 
innovation attributes.  Mass media strategies such as radio, television, and films were 
used as an initial information-spreading source.  Given the sensitive nature of HIV/AIDS 
topics, interpersonal channels of communication were more effective in opening lines of 
communications and building trust between the outreach workers and the target 
audience.  The programs were also sensitive to how the target audience perceived the 
attributes of the innovative HIV/AIDS programs.  For example, the free services and 
colorful vests that were awarded to participants were viewed as a relative advantage.  
The programs also tried to be compatible with the day-to-day lifestyles and values of 
their clients.   
Ash and colleagues77 used the Diffusion of Innovations theory to study adoption 
and implementation of electronically entering physicians’ orders for patient care 
(Physician Order Entry) in 4 hospital sites.  This qualitative study collected data through 
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participant observation, focus groups, and formal face-to-face interviews.  Patterns that 
fit the DOI Theory were then analyzed.  The innovation attributes that were evaluated 
found that Physician Order Entry (POE) has some relative advantage over handwritten 
orders but may not be very compatible with the workflow or needs of users unless the 
hospital system values technology.  Physician Order Entry was rated highly complex 
compared to handwritten orders but low on trialability since the hospitals tended to 
commit to POE without experimenting first.  Since opinion leaders tended to sway the 
decision to implement POE, observability was rated high.  Additional time required was 
resented by some users who perceived the chief benefits to be for someone other than 
themselves.  According to the authors, benefits of POE depend on a critical mass of 
users sharing the order information.  The larger the number of users, the faster POE 
diffused through the hospital social systems. 
Pearcey and Draper78 explored the factors associated with non-utilization of 
research-based preoperative information given to patients in a hospital ward.  Roger’s 
Diffusion of Innovations model of stages in the innovation-decision process supplied the 
framework for both data collection and analysis (Figure 6).  In the knowledge stage, the 
study found that patients were not given adequate preoperative information.  There was 
also a problem of not documenting important comments from patients or other details 
that might be important to recall later.  Staff worked under the assumption that patients 
were already being given adequate preoperative information.   
During the persuasion stage the researchers discussed the perceived 
characteristics of the innovation of a preoperative information protocol with the staff.  
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During the decision stage, staff agreed to write the protocol based on research provided 
by the researchers and use the innovation on a trial basis.  This study did not make it to 
the implementation stage.  It was postulated by the authors that the preoperative 
information protocol was not utilized because the more influential staff in the hospital 
did not feel the innovation was useful.  However, it was felt that the Diffusion of 
Innovations framework could be useful in discovering why this type of protocol is 
rejected or adopted by other hospitals. 
 
 
                       Figure 6  A Model of Stages in the Innovation-Decision Process78 
 
Landrum79 explored the theoretical perspectives of how people adopt innovations 
using the Standard Of Care: Skin Integrity protocol used in a medical intensive care unit 
at a large urban hospital.  The information was used to plan campaigns to introduce 
innovations as a process rather than an outcome in medical settings. Landrum found the 
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rate at which nurses adopt and use research findings has a lag time of 8 to 30 years.  The 
author states: 
In today’s turbulent health care environment, the general public, administrators 
of health care agencies, and economics dictate that we decrease the lag time 
needed to adopt innovation into daily practice.  Failing to do so can result in a 
loss of agency income and a loss of nursing jobs.(p194)  
 
Research by Mary Moore, Dean of Library and Information Resources at the 
State University of Arkansas showed that the adoption of medical innovations such as 
telemedicine is influenced by factors such as socio-economics, demographic, 
psychological and communication related characteristics.80 An interactive video 
(MEDNET) was implemented in 2 remote sites in west Texas where no large cities or 
medical centers were located.  The purpose of the interactive video was to supply 
qualitative health care to underserved patients and to reduce the professional isolation of 
local physicians.80   
The user characteristics of the sites inspired Dr. Moore to investigate physicians’ 
adoption of medical innovations.  While one remote site showed successful results, the 
other was an expensive failure.  Users from the successful site turned out to be recent 
medical graduates, who were assertive and energetic, displaying a humble and altruistic 
attitude but self-confident at the same time.  According to Moore,80 these early adopters, 
acting as true opinion leaders, would be characterized by Roger’s diffusion theory as 
having greater intelligence, abstraction and rationality. 
According to Ference,73 the early adopters of Coleman, Katz, and Menzell’s 
1966 study of the diffusion of a new antibiotic were also acting as opinion leaders: 
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…they were younger (and perhaps more innovative), heavier prescribers of other 
drugs (perhaps from greater exposure to ‘detailing’), more likely to be specialists 
(high status), and to have attended north-central medical schools, to read 
professional journals, attend conferences, and visit other institutions (better 
educated, greater exposure to external sources of communication.) (p166) 
 
Identification of the two major breast cancer genes, BRCA1 and BRCA2 made 
testing for genetic susceptibility possible.  Armstrong and colleagues81 used components 
of the Diffusion of Innovations theory to describe the characteristics of women who 
were early adopters of BRCA1/2 testing.  Variations in seeking BRCA1/2 testing after 
genetic counseling were also evaluated.  The researchers concluded that the use of 
BRCA1/2 testing among women who were counseled is associated with innovative 
characteristics of the participant as well as the perceived compatibility of the test with 
personal values and needs.  Attitudes about complexity and relative advantage of the 
tests were not associated with level of innovativeness. 
Spellman82 stated, “The revelations of genomics have fueled expectations that 
genetics will define human nature and that gene therapy will alter the natural history of 
disease.”(p665)  However, this author is cautious about these expectations when social 
determinants of health are still significant factors globally affecting medicine in the 21st 
century.  In terms of who does or does not have access to genetic services, Evans and 
Britt44 sense that advancement in genetic knowledge will bring a number of scenarios or 
patterns of diffusion, each with its own set of outcomes and implications.  From past 
experience with diffusion of medical innovations such as prenatal diagnosis technology, 
the authors surmise that those who will benefit most from advances in genetic 
knowledge will probably be those who have the resources to do so. 
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Evans and Britt44 observed that there has not been an emphasis on the diffusion 
of knowledge being generated by the Human Genome Project.   According to Jones,83 
“new medical science knowledge usually kick-starts aggressive adoption by providers 
that perceive themselves as front-runners in their service areas.  But this has not been the 
case with the new genetic technology.”(p15)  Emery and Hayflick54 feel that specific 
elements of genetic medicine will require a gradual adoption and incorporation into 
primary care.   
Given the complex nature of genetic knowledge and technologies, as well as the 
complexity involved in their adoption, understanding the diffusion characteristics of 
genomic medicine within a primary care environment will help address the potential 
needs of these physicians as genomic medicine is integrated into their practice.  As most 
of the empirical research of PCPs’ knowledge or attitudes about genomic medicine so far 
has been atheoretical, this study adds to the existing body of knowledge by examining 
the factors proposed by the Diffusion of Innovations theory that may influence PCPs’ 
adoption of genomic medicine into their practice. 
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CHAPTER III 
METHODS 
 
 The proposals for the pilot and final study were reviewed and approved by the 
Institutional Review Board of Texas A&M University (Appendix B).  The purpose of 
the study is to assess whether and to what extent physicians’ perceptions of genomic 
medicine as an innovation influence their likelihood of adopting this innovation into 
primary care. 
 
Design 
 This study employed a survey design.  An instrument to measure the perceptions 
of the characteristics of genomic medicine as an innovation and the likelihood of its 
adoption by primary care physicians was constructed and tested.  Qualitative findings 
from a background study consisting of interviews with 6 primary care providers, 2 health 
educators, 1 geneticist, and 1 genetic counselor were used to inform the development of 
the instrument.   A panel of experts reviewed the questions for content validity.  A pilot 
study to test the questionnaire was conducted with a convenience sample of 50 primary 
care physicians in Texas.  Internal consistency (Cronbach alpha reliability coefficient) 
and factorial structure of the instrument’s scales were assessed during the pilot and final 
studies.  
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Qualitative Background Study  
Nine interviewees from six sites in College Station, Texas were selected for the 
background study.  The sites included a prenatal clinic, a family planning clinic, and a 
genetic counseling clinic, all located in the same community health center but without 
affiliation with each other.  These three clinics serve all populations but most clients are 
funded primarily by Medicaid and federal Maternal and Child Health Bureau Title V 
funds.  Interviews were also conducted at a fourth clinic site that provides service only to 
their health maintenance organization (HMO) clients.  The fifth and sixth interview sites 
were Texas A&M University and the Texas A&M University Health Science Center. 
Individuals from five professional groups participated in an interview process 
after informed consent was obtained.  The interviewees included 2 family practice 
physicians, 2 nurse practitioners, 2 social workers (1 was also a genetic counselor), 2 
health educators and 1 geneticist. The interviewees were chosen from referrals made by 
colleagues and other study participants.  Interview sessions were typically from 30 
minutes to 1 ½ hours in length.  Three interview guides were developed; one for the 
family physicians, nurse practitioners, and social workers, one for geneticists, and 
another for the health educators (Appendix C).  The interview guides were composed 
primarily of open-ended questions.  Using a grounded theory approach elicited detailed 
information while allowing flexibility for probing questions and issues that study 
participants considered important.  All interviews were tape recorded and transcribed 
verbatim.  A content analysis of the transcripts informed the development of the 
instrument for this study. 
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Instrument 
 The principal investigator developed the pencil-and-paper, self-administered 
instrument used in this study.  The questionnaire was brief (four-pages) in order to better 
fit a physician’s busy time schedule and hopefully increase the historically low response 
rate for physician surveys.   The questionnaire consisted of 35 questions to measure the 
perceived characteristics of the innovation of genomic medicine.  There were also six 
demographic questions.  Scales were designed to measure relative advantage, 
compatibility, complexity, trialability, and observability of genomic medicine.  A scale 
to measure the likelihood of primary care physicians’ adopting genomic medicine was 
also developed.  A copy of the instrument is included in Appendix D. 
 Rates of diffusion and adoption depend to a large extent on how certain 
characteristics of the innovation interact with the targeted social system.  The behaviors 
or characteristics of the system’s individual members can also dictate the rate of 
adoption.   Some individuals or “innovators” within the system are more influential than 
others in affecting the flow of diffusion and adoption.70  While characteristics of 
adopters are crucial for understanding the adoption process, it was necessary to keep the 
questionnaire brief and only the characteristics of the innovation were measured in this 
study.   
The construct “perceptions” is being understood in this study as “attitudes.”  
Operationally, attitudes were measured through two dimensions:  beliefs (outcome 
expectations) and values (outcome expectancies).   Expectation and expectancy questions 
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were asked for each of the characteristics of the innovation of genomic medicine:  
relative advantage, compatibility, complexity, trialability, and observability.   
Multiplying each expectation and corresponding expectancy scores and summing 
these products computed respondents’ “perception” scores for each of the characteristics.  
For example, the score for the relative advantage scale is a result of the application of 
the formula below, where 1a through 1d are the items measuring the advantages of 
genomic medicine (beliefs) and 2a through 2d measure how important the perceived 
advantages of genomic medicine are to the respondent (values).   
Σ (1a * 2a +1b * 2b + 1c * 2c +1d * 2d) 
The four expectation items use a five point agree-disagree Likert scale and the 
four expectancy items (How important is it to you that…?), use a five point important-
not important Likert scale, for response.  A lower score for this scale indicates a stronger 
perception of the relative advantage of genomic medicine.     
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The eight items developed to measure relative advantage of genomic medicine  
are based on the “uses of clinically applicable gene tests” derived from GeneTests, a 
website funded by the National Institutes of Health, the Human Resource and Services 
Administration, and the Department Of Energy.  The website is available at 
http://geneclinics.org.  This scale achieved an internal consistency of .79 (n=21) in the 
pilot study and .73 (n=400) in the final study.   
A factor analysis was conducted for the pilot and final studies to determine if 
perceived attribute items clustered as expected.  For the analysis, the principle 
components method was used with a varimax rotation.  The factor analysis for relative 
advantage revealed three major factors explaining 68.3% of the total variance (Table 2).  
All items that loaded on factor 1 assessed the expectations and expectancies of 
“predicting genetically inherited disorders.”  Factor two’s items related to 
“pharmacogenomics” and factor 3 contained the expectation and expectancy of 
“preimplantation diagnosis.”  
  
 
 
 
 
 
 
 
 Table 2 
Final Study:  Factor Loadings for Relative Advantage Items 
N=400 
 
                            Factor 
         1                              2                              3  
Factor 1 –  Predictive genomics  
   I believe one of the advantages of genomic medicine is to…  
      1b.  Perform carrier testing for a possible autosomal recessive  
             disorder before the onset of symptoms. 
      1c.  Supplement a family history in predicting the risk of a health 
             individual developing a disease. 
   How important is it for you to be able to… 
      2a.  Test whether an individual possesses a copy of a mutated gene  
             for an autosomal recessive disorder before the onset of symptoms? 
      2c.  Supplement a family history in predicting the risk of a healthy 
             individual developing a disease? 
 
Factor 2 – Pharmacogenomics 
   I believe one of the advantages of genomic medicine is to… 
      1d.  Supplement knowledge of previous medical history in predicting 
             which medications will be most effective for specific patients. 
   How important is it for you to be able to… 
      2d.  Supplement previous knowledge of medical history in predicting 
             which medications will be most effective for specific patients? 
 
Factor 3 – Preimplantation diagnosis 
   I believe one of the advantages of genomic medicine is to… 
      1a.  Diagnose a genetic condition in an embryo before it is implanted                               
             instead of waiting and doing an ultrasound later in the pregnancy. 
   How important is it for you to be able to… 
      2a.  Detect a genetic condition in an embryo before it is implanted? 
       
 
        
        .766                              --                                --               
 
        .775                              --                                --               
         
 
        .649                              --                                --               
 
        .750                              --                                --               
 
 
 
           --                              .861                             --               
 
 
           --                              .908                             --      
 
 
 
 
 
           --                                --                               .835 
 
 
           --                                --                               .843  
 
% of Variance                                                                                                                     28.050                    21.463                        18.832 
Cumulative %                                                                                                                     28.050                    49.513                         68.346 
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 Compatibility was conceptualized as a latent variable measured by 3 indicators, 
compatibility with professional beliefs, compatibility with personal beliefs and values, 
and compatibility with current medical practice.  The outcome expectation questions for 
compatibility with professional and compatibility with personal beliefs and values were 
adapted from similar questions found in The University of Glasgow’s e-mail 
questionnaire on ethical problems in medical genetics.  This questionnaire is available at 
http://www.gla.ac.uk/departments/medical genetics/mbethicsq.htm.  The outcome 
expectancy questions, developed by the principal investigator, were intended to measure 
how important it is for respondents that genomic medicine be compatible with their 
professional and personal beliefs and values, as well as with their current medical 
practice.  The indicators “professional beliefs” and “personal values and beliefs” are 
each measured with two items for expectations, using a five point agree-disagree Likert 
scale and 1 item for expectancy, using a five point important-not important Likert scale.  
A lower score on these two scales indicate a stronger perception of the compatibility of 
genomic medicine with the professional beliefs and the personal beliefs and values of the 
primary care physicians.   
The compatibility with current medical practice scale was informed by both the 
literature review and the qualitative background study which confirmed that many 
primary care providers lacked the time and skills to incorporate genetic counseling, more 
detailed family history, or genetic testing into their practice. The compatibility with 
“current medical practices” indicator is measured with three expectation items, using a 
five point agree-disagree Likert scale.  The response “already incorporated” was added 
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to measure the number of respondents that have already incorporated certain tasks of 
genomic medicine into their practice.   The one expectancy item uses a five point 
important-not important Likert scale, for response. A lower score for this scale indicates 
a stronger perception of the compatibility of genomic medicine with the primary care 
physicians’ current medical practice.   
The factor analysis showed that the compatibility indicators were measuring 4 
components accounting for 74.1% of the variance (Table 3).  All of the items for the 
compatibility with the current medical practice scale loaded on factor one.  However,  
“How important is it to you for genomic medicine to be easily incorporated into your 
primary care practice?” had a small loading of .392.  The items within factor 2 were 
measuring the professional and personal beliefs toward predictive testing.  Factor 3 
contained professional and personal beliefs toward terminating a pregnancy when the 
child would be severely affected.  Items within factor 4 related to the importance of 
genomic medicine being consistent with professional and personal beliefs and values.  
Because the professional and personal belief items tended to cluster together in the factor 
analysis, these two indicators were combined to form one variable.  Separately the 
internal consistency was low for “compatibility with professional beliefs” and 
“compatibility with personal beliefs” for both the pilot (.39, .57, n=21) and final studies 
(.35, .30, n=400).  Combining the two indicators raised the internal consistency to .65 
(n=400) for the new variable compatibility with professional/personal beliefs and 
values.  The compatibility with current medical practice scale achieved an internal 
consistency of .80 (n=21) in the pilot study and .74 (n=400) in the final study.   
 
  
Table 3 
Final Study:  Factor Loadings for Compatibility Items 
N=400 
 
                                       Factor 
         1                   2                      3                    4  
Factor 1 – Ease of incorporating genomic medicine into current practice    
      9.  How important is it to you for genomic medicine to be easily incorporated  
           into your primary care practice? 
    10.  Genetic counseling could easily be incorporated into my primary care practice.   
    11.  Taking a more detailed family history could easily be incorporated into my 
           primary care practice. 
    12.  Genetic testing could easily be incorporated into my primary care practice. 
       
Factor 2 – Predictive testing beliefs and values  
      4.  Offering predictive testing for diseases in which there is no available treatment or 
           cure (such as Huntington’s Disease) is consistent with my professional standards. 
      6.  Predictive testing for diseases in which there is no available treatment or cure 
           (such as Huntington’s Disease) is compatible with my personal values. 
 
Factor 3 –Termination of pregnancy beliefs and values 
      3.  Termination of pregnancy when there is a substantial risk that if a child were born 
            it would suffer from a serious mental or physical abnormality is consistent with 
            my professional standards. 
      5.  Termination of pregnancy when there is a substantial risk that if a child were born 
           it would suffer from a serious mental or physical abnormality is consistent with 
           my personal values. 
 
Factor 4 – Consistency of genomic medicine with beliefs and values  
       7.  How important is it to you for genomic medicine to be consistent with your  
            professional standards?   
       8.  How important is it to you for genomic medicine to be consistent with your  
            personal values?   
       
 
        .392                   --                       --                      --          
 
        .868                   --                       --                      --          
        .801                   --                       --                      -- 
 
        .848                   --                       --                      -- 
 
 
           --                    .916                   --                      --          
 
           --                    .904                   --                      -- 
 
 
 
           --                     --                     .893                   -- 
 
 
           --                     --                     .927                   -- 
 
 
 
 
           --                     --                      --                      .853 
 
           --                     --                      --                      .868 
 
% of Variance                                                                                                                     23.053             17.782            17.746           15.543 
Cumulative %                                                                                                                     23.053             40.836            58.582           74.125
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    The complexity scale was also informed by the literature review and qualitative 
background study; both found that locating genetic services and staying updated on 
genomic medicine-related knowledge were barriers for primary care providers. This 
scale consists of two items for expectations and two items for expectancies, using a five 
point agree-disagree and easy-difficult Likert scale, for response. A higher score for this 
scale signifies a stronger perception of the complexity of genomic medicine.  The 
Cronbach alpha for this scale was .62 (n=21) in the pilot study and .60 (n=400) in the 
final study.  The factor analysis for the scale measuring complexity revealed two major 
factors accounting for 73.8% of the variance (Table 4).  The two expectancy items for 
this scale fell within factor 1 and the 2 expectation items fell within factor two. 
The trialability scale was designed to measure the extent to which genomic 
medicine can be experimented before a commitment to full incorporation is made.  The 
items were informed by the literature review and qualitative background study.  Item 16, 
“Genetic technologies, unlike other medical technologies, cannot be incorporated on a 
trial basis,” was reverse-coded in both the pilot and final study.  Trialability is measured 
with two items for expectations and two items for expectancies, using a five point agree-
disagree, important-not important Likert scale, for response.  A lower score on this scale 
indicates a stronger perception that genomic medicine can be incorporated on a trial 
basis.  
 
 Table 4 
Final Study:  Factor Loadings for Complexity Items 
N=400 
 
                                       Factor 
                         1                              2                             
Factor 1 – Complexity of genomic medicine expectancies 
    How important is it for you… 
       14a.  To be able to locate available genetic services without difficulty? 
       14b.  To easily stay updated on genomic medicine-related knowledge? 
            
       
Factor 2 – Complexity of genomic medicine expectations 
    How easy or difficult is it for you to… 
       13a.  Locate available genetic services? 
       13b.  Stay updated on genomic medicine-related knowledge? 
 
       
 
         
                          .891                              --             
                          .882                              --                               
      
 
                             
                             
                              --                               .739                          
                              --                               .861 
 
% of Variance                                                                                                                                       41.134                       41.134           
Cumulative %                                                                                                                                       32.684                       73.818             
 
 
 
 
 
54
 
 55
The four item scale achieved an internal consistency of .79 (n=21) in the pilot 
study.  However, reverse-coded item 16 caused the reliability score to drop to .30 
(n=400) in the final study.  Item 16 was dropped from the final analysis, raising the 
internal consistency score to .65 (n=400).  The factor analysis for the three item scale for 
trialability showed all items loading on the same component accounting for 47.2% of the 
variance (Table 5).   
The observability scale, also informed by the literature review, was based on the 
degree to which the benefits of genomic medicine were being observed by the 
respondents. Two expectation items and two expectancy items were used to measure 
observability, using a five point agree-disagree, important-not important Likert scale for 
response.  A lower score for this scale indicated a stronger perception that colleagues of 
the respondents are adopting genomic medicine into their practice.  Reliability for this 
scale was .64 (n=21) for the pilot and .60 (n=400) for the final study.  The factor analysis 
showed the observability scale loading on two components.  Factor 1 contained the 
expectancy items and factor 2 contained the expectation items, accounting for 80% of 
the variance (Table 6). 
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The factor analysis for the scaled dependent variable “Likelihood of PCPs 
adopting genomic medicine” showed that all five items were measuring this component, 
accounting for 57% of the variance (Table 7).  This scale, which achieved an internal 
consistency of .78 (n=21) in the pilot study and .81 (n=400) in the final study was based 
on the “uses of clinically applicable gene tests” derived from GeneTests (available at 
http://geneclinics.org).  Adding the respondents’ scores from the five items that question 
primary care physicians’ likelihood of adopting genomic medicine computed the score 
for this scale. The scale used a five point likely-not likely Likert scale, for response. The 
response “I Already Am” was added to measure the number of respondents that are  
already using clinical applications of genomic medicine.  A lower score indicated a 
stronger likelihood of adopting the innovation of genomic medicine.     
 
Pilot Study 
 A pilot study was conducted to pretest the questionnaire with a convenience 
sample of 50 primary care physicians in Texas.  The physicians were chosen among 
acquaintances and from the telephone directory for Bryan, College Station, San Antonio, 
and Austin, Texas. The survey was accompanied by a cover letter explaining the study 
 
 
 
 
 
 Table 5 
Final Study:  Factor Loadings for Trialability Items 
N=400 
 
                                       Factor 
                                          1                                            
Factor 1 – Trialability of genomic medicine – expectations and expectancies 
       15.    Genetic services can gradually be incorporated into primary care practice.             
       16.    Genetic technologies, unlike other medical technologies, cannot be 
                 incorporated on a trial basis. 
              How important is it for you…   
       17a.   Be able to gradually incorporate genetic services into your practice 
       17b.   Incorporate technologies that you have tried first? 
 
       
 
                                             .730                                
                                            -.466                                   
      
 
                                             .795                                             
                                             .711 
% of Variance                                                                                                                                                        47.202 
Cumulative %                                                                                                                                                        47.202 
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 Table 6 
Final Study:  Factor Loadings for Observability Items 
N=400 
 
                                       Factor 
                         1                              2                             
Factor 1 – Observability of genomic medicine expectancies 
    Before you consider adopting genomic medicine into your practice,  
    how important is it for you that your colleagues… 
       19a.  Adopt genetic testing into their practice? 
       19b.  Assist patients in making decisions regarding genetic services? 
            
Factor 2 – Observability of genomic medicine expectations 
    Most of my colleagues are… 
       18a.  Adopting genetic testing into their practice. 
       18b.  Assisting patients to make decisions regarding genetic services. 
 
       
 
         
                           
                          .868                              --             
                          .852                              --                               
      
 
                             
                             --                              .920                            
                             --                              .923 
 
% of Variance                                                                                                                                       42.803                      42.803           
Cumulative %                                                                                                                                       37.227                      80.030         
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 Table 7 
Final Study:  Factor Loadings for PCPs Likelihood to Adopt Items 
N=400 
 
                                       Factor 
                                          1                                            
Factor 1 – Likelihood to adopt genomic medicine 
    For your patients, how likely are you to…    
       20a.  Order carrier testing for a possible autosomal recessive disorder?                            
       20b.  Order a preimplantation diagnosis to check for genetic disease in an embryo? 
       20c.  Order a predictive test for risk of disease? 
       20d.  Provide pre-conception counseling? 
       20e.  Refer them for a genetic consultation? 
 
       
 
                                              
                                             .835                                
                                             .627                                   
                                             .797 
                                            .750                                             
                                             .772 
% of Variance                                                                                                                                                        57.695 
Cumulative %                                                                                                                                                        57.695 
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and an informed consent form; both were previously approved by the Institutional 
Review Board of Texas A&M University (Appendix E). A self-addressed stamped 
envelope was included to facilitate return of the survey.  A return fax number was given 
as an alternative to returning the completed survey by mail.  
  Twenty-one physicians, 18 male and 3 female, returned the questionnaire for a 
response rate of 42%.  Their ages ranged from 32 to 70 years (Table 8).  Sixteen of the 
respondents practice in a private setting and 5 in a group setting. The practices were 
located in Bexar, Brazos, Dewitt, Harris, and Travis counties (Table 9). 
 Table 10 shows the majority of respondents agreed that preimplantation 
diagnosis, carrier testing, using genomic medicine to supplement a family history in 
predicting disease risk, and supplementing knowledge of previous medical history to 
predict effective medication were all relative advantages of genomic medicine.  Except 
for preimplantation diagnosis where responses were divided, the selected applications 
for genomic medicine were considered “extremely important” or “somewhat important” 
by more than half of the respondents. 
 A majority of the responding physicians feel that predictive testing for diseases 
for which there is no cure is consistent with both their professional and personal beliefs.   
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                                                     Table 8 
                  Pilot Study: Selected Demographic Characteristics 
Variable No. (n=21) % 
 
Current age  
  
   Under 40     4 19.0 
   40-54   11 52.4 
   55 and Over     6 28.6 
Gender   
   Male   18 85.7 
   Female     3 14.3 
Ethnicity   
   White   17 81.0 
   Black     0      0 
   Hispanic     0      0 
   Asian/Pacific Islander     4 19.0 
Medical School   
   In-state   14 66.7 
   Out-of-state     6 28.6 
   Out-of-country     1   4.7 
Year of Graduation   
   1975 and later    7 33.3 
   1976-1989    8 38.1 
   1990 and earlier    6 28.6 
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Table 9 
Pilot Study: Professional Specialty of Physicians 
Specialty  No. (n=21) % 
Internal Medicine 5 23.8 
Pediatrics 3 14.3 
Obstetrics and/or Gynecology 2   9.5 
Family Medicine 9 42.9 
General Practice 2   9.5 
 
Pilot Study: Practice Setting of Physicians 
Professional Practice                No. (n=21)  % 
Private 
Group 
                16 
                  5 
         76.2 
         23.8 
 
Pilot Study: County of Physicians’ Practice 
County               No. (n=21) % 
Bexar 
Brazos 
Dewitt 
Harris 
Travis 
                9 
                5 
                3 
                2 
                2 
42.9 
23.8 
14.3 
  9.5 
  9.5 
 
 
 
 
 
 
 
 Table 10 
Pilot Study:  Percentage Distribution of Responses Regarding the Perceptions of the Relative Advantage of Genomic Medicine 
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  1.  I believe one of the advantages of                  
    genomic medicine  is to…                             n=21   
Strongly 
Agree 
Agree I’m not  
Sure 
Disagree Strongly
Disagree          
 
a.  Diagnose a genetic condition in an embryo before it is 
     implanted instead of waiting and doing an ultrasound  
     later in the pregnancy. 
 
b.  Perform carrier testing for a possible autosomal 
     recessive disorder before the onset of symptoms. 
   % 
14.3 
 
 
 
38.1 
 
 
   % 
42.9 
 
 
 
52.4 
   % 
19.0 
 
 
 
 9.5 
   % 
14.3 
 
 
 
-- 
  % 
9.5 
 
 
 
-- 
c.  Supplement a family history in predicting the risk 
     of a healthy individual developing a disease. 
28.6     
      
61.9 9.5 -- --
 
d.  Supplement knowledge of previous medical history in  
     predicting which medications will be most effective 
     for specific patients. 
 
 
23.8 
 
52.4 
 
9.5 
 
14.3 
 
-- 
2.  How important is it for you to be able to…  n=21 
                                                                           
                                                                                                               
Extremely 
Important 
 
   %  
Somewhat 
Important 
 
   % 
I’m not 
Sure 
 
   % 
Not Very 
Important 
  
   % 
Not Important 
At All  
 
   % 
a.  Detect a genetic condition in an embryo before 
     it is implanted? 
19.0 23.8 9.5 28.6 19.0
 
b.  Test whether an individual possesses a copy of 
      a mutated gene for an autosomal recessive disorder before 
      the onset of symptoms? 
 
38.1 
 
33.3 
 
14.3 
 
 4.8 
 
 9.5 
 
c.  Supplement a family history in predicting the risk of  
     a healthy individual developing a disease? 
 
38.1 
 
52.4 
 
 -- 
 
 -- 
 
 9.5 
 
d.  Supplement previous knowledge of medical history in 
     predicting which medications will be most effective for 
     specific patients? 
 
38.1 
 
52.4 
 
 4.8 
 
 -- 
 
 4.8 
Cronbach α .79 (8 items)
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Less than half agreed that termination of pregnancy when there is a substantial risk the 
child would suffer from serious abnormalities is consistent with their professional or 
with their personal beliefs (Table 11). 
 Most of the physicians responded that it was important to be able to locate 
genetic services as well as stay updated on genomic medicine-related knowledge, but 
33.4% and 52.4%, respectively, acknowledged that such tasks were either “somewhat” 
or “extremely” difficult for them (Table 12).  The majority of respondents felt it was 
important to be able to gradually incorporate genetic services into their practice (Table 
13).  A majority of the physicians disagreed that their colleagues were adopting genetic 
testing into their practice. However, it was an important consideration before most 
respondents adopt genetic testing into their practice (Table 14). 
 Table 15 shows that none of the primary care physicians in the pilot study have 
already adopted any of the selected applications of genomic medicine into their practice.  
Most of them responded that they were likely to adopt all of the applications of genomic 
medicine except preimplantation diagnosis to check for disease in an embryo. 
   
 
 Table 11 
Pilot Study: Percentage Distribution of Responses Regarding the Perceptions of Compatibility of Genomic Medicine 
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                                                                      n=21 
                                                                                  
Strongly 
Agree 
Agree I’m not  
Sure 
Disagree Strongly
Disagree         
 
3.  Termination of pregnancy when there is a substantial 
      risk that if a child were born it would suffer from a serious 
      mental or physical abnormality is consistent with my 
     professional beliefs. 
 
4.  Offering predictive testing for diseases in which there is no 
     available treatment or cure (such as Huntington’s Disease) 
     is consistent with my professional beliefs. 
 
5.  Termination of pregnancy when there is a substantial  
      risk that if a child were born it would suffer from a serious 
      mental or physical abnormality is compatible with my  
      personal values. 
 
6.  Predictive testing for diseases in which there is no available 
     treatment or cure (such as Huntington’s Disease) is 
    compatible with my  personal values.                    
   % 
14.3 
 
 
 
 
23.8 
 
 
 
14.3 
 
 
 
 
28.6 
   % 
33.3 
 
 
 
 
61.9 
 
 
 
28.6 
 
 
 
 
52.4 
   % 
14.3 
 
 
 
  
4.8 
 
 
 
14.3 
 
 
 
 
4.8 
   % 
23.8 
 
 
 
 
9.5 
 
 
 
14.3 
 
 
 
 
9.5 
   % 
14.3 
 
 
 
 
-- 
 
 
 
28.6 
 
 
 
 
4.8 
 
                     
      
                                                                    n=21                       Extremely            Somewhat       I’m not             Not Very         Not Important 
                                                                                                                 Important             Important         Sure                Important        At All 
                                                                                                                  %    %   %   %   % 
7.  How important is it to you for genomic medicine to be 
     consistent with your professional standards? 
 
8.  How important is it to you for genomic medicine to be  
     compatible with your personal values? 
 
9.  How important is it to you for genomic medicine to be 
     easily incorporated into your primary care practice? 
 
61.9 
 
 
52.4 
 
 
28.6 
33.3 
 
 
33.3 
 
 
57.1 
-- 
 
 
-- 
 
 
4.8 
-- 
 
 
9.5 
 
 
-- 
4.8 
 
 
4.8 
 
 
9.5 
 
 
 Table 11 continued 
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                                                                     n=21 Already 
Incorporated 
Strongly 
Agree 
Agree Disagree Strongly
Disagree        
 
10.  Genetic counseling could easily be incorporated into 
        my primary care practice. 
 
11.  Taking a more detailed family history could easily 
        be incorporated into my primary care practice. 
 
12.  Genetic testing could easily be incorporated into 
        my practice. 
 
 
  % 
4.8 
 
 
-- 
 
 
-- 
  % 
4.8 
 
 
9.5 
 
 
9.5 
   % 
52.4 
 
 
71.4 
 
 
42.9 
   % 
28.6 
 
 
14.3 
 
 
38.1 
  % 
9.5 
 
 
4.8 
 
 
9.5 
Cronbach α  
 Professional beliefs .39 (3 items) 
 Personal beliefs & values .57 (3 items) 
 Current medical practices .80 (4 items) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 12 
Pilot Study:  Percentage Distribution of Responses Regarding the Perceptions of the Complexity of Genomic Medicine 
13.  How easy or difficult is it for you to…            n=21 
                                                                                 
Extremely 
Easy 
Somewhat 
Easy 
I’m not  
Sure 
Somewhat 
Difficult 
Extremely  
Difficult         
 
a. Locate available genetic services? 
 
b. Stay updated on genomic-related knowledge? 
  % 
9.5 
 
-- 
   % 
42.9 
 
33.3 
   % 
14.3 
 
14.3 
   % 
28.6 
 
42.9 
  % 
4.8 
 
9.5 
 
 
 
 
 
  
     
 
 
 
 
 
14.  How important is it for you…                         n=21 
                                                                                
 
Extremely 
Important 
 
   % 
Somewhat 
Important 
 
   % 
I’m not 
Sure 
 
  % 
Not Very 
Important  
 
  % 
Not Important 
At All   
 
  %           
 a.  To be able to locate available genetic services 
     without difficulty? 
38.1 57.1 -- -- 4.8
 
b.  To easily stay updated on genomic medicine-related 
      knowledge? 
 
28.6 
 
61.9 
 
-- 
 
 4.8 
 
 4.8 
 
 
 
 
 
 
 
  
 
  
 
  
Cronbach α .62 (4 items) 
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 Table 13 
Pilot Study:  Percentage Distribution of Responses Regarding the Perceptions of the Trialability of Genomic Medicine 
                                                                           n=21 
                                                                            
Strongly 
Agree 
Agree 
 
I’m not  
Sure 
Disagree 
 
Strongly 
Disagree        
 
15.  Genetic services can gradually be incorporated into 
        primary care practice. 
 
16.  Genetic technologies, unlike other medical 
        technologies, cannot be incorporated on a trial 
        basis. 
  % 
4.8 
 
 
-- 
   % 
71.4 
 
 
28.6 
   % 
14.3 
 
 
19.0 
  % 
4.8 
 
 
42.9 
  % 
4.8 
 
 
9.5 
       (reverse-coded) 
 
 
 
 
  
 
 
 
 
 
17.  How important is it for you…                    n=21 
                                                                           
 
Extremely 
Important 
 
   % 
Somewhat 
Important 
 
   % 
I’m not 
Sure 
 
   % 
Not Very 
Important 
  
  % 
Not Important 
At All      
 
  %         
a.  To be able to gradually incorporate genetic services 
     into your practice? 
14.3 
 
57.1   14.3 4.8 9.5 
 
b.  Incorporate technologies that you have tried first? 
 
9.5 
 
 
57.1 
 
23.8 
 
 -- 
 
 9.5 
 
 
 
 
 
 
 
  
 
  
 
  
Cronbach α .79 (4 items) 
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 Table 14 
Pilot Study:  Percentage Distribution of Responses Regarding the Perceptions of the Observability of Genomic Medicine 
18.  Most of  my colleagues are…                             n=21 
                                                                                    
Strongly 
Agree 
Agree 
 
I’m not  
Sure 
Disagree 
 
Strongly 
Disagree          
 
a.  Adopting genetic testing into their practice. 
 
b.  Assisting patients to make decisions regarding 
     genetic services. 
  % 
-- 
 
-- 
 
  % 
9.5 
 
19.0 
 
   % 
23.8 
 
28.6 
 
   % 
52.4 
 
33.3 
 
   % 
14.3 
 
19.0 
 
 
 
 
 
  
   
 
 
 
 
 
19.  Before you consider adopting genomic             n=21 
       medicine into your practice, how important      
       is it for you that your colleagues…                                
                                                                          
Extremely 
Important 
 
 
   % 
Somewhat 
Important 
 
 
   % 
I’m not 
Sure 
 
 
  % 
Not Very 
Important  
 
 
   % 
Not Important 
At All  
 
 
  %               
 a.  Adopt genetic testing into their practice? -- 
 
61.9 9.5 19.0 9.5
b.  Assist patients in making decisions regarding  
     genetic services? 
14.3 
 
 
57.1 
 
9.5 
 
19.0 
  
-- 
 
 
 
 
 
 
 
 
  
 
  
 
  
Cronbach α .64 (4 items) 
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 Table 15 
Pilot Study:  Percentage Distribution of Responses Regarding the Likelihood of  PCPs Adopting Genomic Medicine 
20.  For your patients, how likely are you to…    n=21 
                                                                               
I Already 
Am 
Extremely 
Likely 
Somewhat 
Likely 
Not 
Likely 
Not Likely 
At All            
 
a.  Order carrier testing for a possible autosomal recessive 
      disorder? 
 
b.  Order a preimplantation diagnosis to check for genetic 
      disease in an embryo? 
 
c.  Order a predictive test for risk of disease? 
 
d.  Provide pre-conception counseling? 
 
e.  Refer them for a genetic consultation? 
 % 
-- 
 
 
-- 
 
 
-- 
 
-- 
 
-- 
   % 
14.3 
 
 
9.5 
 
 
9.5 
 
23.8 
 
52.4 
   % 
66.7 
 
 
23.8 
 
 
66.7 
 
33.3 
 
38.1 
  % 
4.8 
 
 
28.6 
 
 
14.3 
 
19.0 
 
4.8 
   % 
14.3 
 
 
38.1 
 
 
9.5 
 
23.8 
 
4.8 
      
Cronbach α .78 (5 items) 
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Final Study 
 The pilot study was conducted between March and April of 2003.  After 
reviewing the internal consistency scores and factorial structure of the instrument’s 
scales, the survey was not changed for the final study.  The final study was conducted 
between April 15, 2003 and June 1, 2003.  The 42% response rate for the pilot study lent 
support to the need to choose an adequate sample size for the final study that would still 
obtain a representative sample of the target population despite a low response rate. 
 
Sample  
 The population of interest for this study is primary care physicians practicing in 
the state of Texas.  A random stratified sample of primary care physicians (N=1350) was 
chosen from a sampling frame obtained from the Texas State Board of Medical 
Examiner’s December 2002 directory of practitioners.  The database was sorted into the 
target primary care specialties (internal medicine, obstetrics and gynecology, pediatrics, 
family practice, general practice).  The obstetrics and gynecology group included 
physicians who specialized in obstetrics, gynecology, or both obstetrics and gynecology.  
The pediatric group included all subspecialties such as pediatric endrocrinology, 
pediatric hematology/oncology, pediatric radiology, pediatric allergy, and pediatric 
cardiology.   
All records of physicians that were not active in practice or direct patient care, 
retired, or deceased were excluded from the sampling frame.  Records that did not show 
Texas as the practice state also were eliminated.  A proportional sample was randomly 
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selected from each stratum (internal medicine, obstetrics and gynecology, pediatrics, 
family practice, general practice) using a table of random numbers.  The sampling 
fractions were combined to form an estimate for the population.  For a population size of 
21,306 licensed primary care physicians as reported by the Texas State Board of Medical 
Examiners (December 2002), a total sample size of 377 was needed to reach statistical 
representation.84  The adjusted sampling frame of 17,445 active primary care physicians 
did not alter this figure.  The random sample of N=1350 was based on a response rate of 
30%, common for this population, which would obtain slightly more (405) than the 
required sample of 377, [1350(.30) = 405] (Table 16).   
 
 
Table 16 
Proportional Stratified Sample of Primary Care Physicians 
PCPs        Population 
                 N      % 
To Be 
Mailed Out 
Sample Size 
Needed 
Family Practice               6,285 (30%) 405 121 
General Practice               1,159 (5%) 67 20 
*Obstetric/Gynecology               3,030 (14%) 189 57 
Internal Medicine               6,827 (32%) 432 130 
Pediatrics               4,005 (19%) 257 76 
Total                            21,306 (100%)       1,350                   404 (~30%)  
* Obstetricians and gynecologists were added to the Obstetric/Gynecology stratum due to low 
sample size needed. [Ob, 37 (<1%), Gyn, 201 (<1%].  Only a sample size of 1 and 4, 
respectively, was needed. 
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Design and Data Collection 
 This study consisted of a survey design.  The sample was surveyed by mailed 
questionnaire in 3 waves.  The first wave was a mail-out package containing a cover 
letter, questionnaire, informed consent form, and a stamped preaddressed envelope 
(Appendix F).  All surveys were number-coded to allow for additional mail outs to non-
responders.   To ensure confidentiality, no names were used to identify respondents.  
Approximately 2 weeks after the first mail-out, reminder post cards were sent to those 
who had not responded.  Due to the historically low response rate from physicians, a 
second mail-out package had been budgeted for the third wave to be sent out to the 
remaining non-responders approximately 5 weeks after the initial mail-out.  In addition 
to the stamped preaddressed envelope, the respondents were given a return fax number 
in an effort to increase the response rate.  The three mail-outs (first questionnaire packet, 
reminder postcards, second questionnaire packet) resulted in 379 completed surveys or a 
28% response rate.  Thirty-five surveys were returned because of unknown addresses or 
because the physician declined to participate.  No differences were found between pilot 
study respondents and final study respondents.  The pilot study data were merged with 
the final study’s data increasing the sample size to 400 (379+21).  Ten questionnaires 
arrived after the analyses were completed and will be included in future publications of 
this study.   
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Data Analysis 
 Data were analyzed with the assistance of the statistical software SPSS®, version 
11.0.   Descriptive statistics were utilized to assess distribution of responses and to 
assess patterns of skewness and kurtosis; correlational techniques were employed to 
study the zero-order relationships (their strength and direction) among variables.  
Multivariate techniques such as multiple regression and factor analysis were also used to 
examine interactions among variables, structure of the latent variable, and for 
comparisons of groups of adopters (those not adopting the innovation versus adopters), 
and/or demographic comparisons.  Structural equation modeling techniques were also 
employed to test the proposed theoretical model and to assess patterns of prediction for 
different groups of respondents (private vs. group practice). 
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CHAPTER IV 
RESULTS 
 
Analyses 
 
Relationships were examined among perceived relative advantage, perceived 
compatability, a latent variable measured with 2 indicators ( compatibility with 
professional/personal beliefs and values, and compatibility with current medical 
practice), perceived complexity, perceived trialability, perceived observability, and 
likelihood of PCPs adopting genomic medicine.  The social system (private or group 
professional practice) was tested for a possible moderating effect upon the dependent 
and predictor variables (Figure 7).  
Descriptive statistics were utilized to assess distribution of responses and to 
assess patterns of normality (skewness: kurtosis); correlational techniques were 
employed to study the zero-order relationships (their strength and direction) among 
variables.  Multiple regression and factor analysis were also used to examine interactions 
among variables, structure of the latent variable, and for comparisons of groups of 
adopters (those not adopting the innovation versus adopters), and/or demographic 
comparisons.  Structural equation modeling techniques were also employed to test the 
conceptual model and to assess patterns of prediction for different groups of respondents 
(private vs. group practice). 
To reduce moderate positive kurtosis (3.850), a square root transformation was 
applied to variable 1c – “I believe one of the advantages of genomic medicine is to  
 
                                                    
                                                   Perceived Characteristics of Genomic Medicine 
                                                                     Expectations/Expectancies 
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Complexity 
Trialability 
Observability 
 
Compatibility
Personal/Professional 
   beliefs and values 
Current Medical 
Practices 
Relative Advantage
Likelihood of 
PCPs Adopting 
Genomic Medicine
 
 
 
 
 
                                                                  Nature of Social System (moderator) 
                                                                               
 
Figure 7  Model to Assess Likelihood of PCPs Adopting Genomic Medicine 
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supplement a family history in predicting the risk of a healthy individual developing a 
disease” – for all data analysis.  A logarithmic transformation was used to reduce the 
substantial positive kurtosis of variable 7 (4.494) – “How important is it to you for 
genomic medicine to be consistent with your professional standards?”85 
 
Missing Values 
 
Missing data almost always generate analytical problems for which there is no 
ideal solutions.85 Two questionnaires that were 25 to 50% incomplete were deleted from 
the study.  Otherwise, responses to the questionnaires contained a small number of 
missing data points.  Mean substitution was used on thirty-eight questionnaires that had 
10% or less missing data points.  The mean substitution procedure is considered 
conservative because “the mean for the distribution as a whole does not change and the 
researcher is not required to guess at missing values.”85 (p62) Missing values were replaced 
with the means of the specific scale items prior to analysis.  For example, cases with 
missing values in item 1a had the mean for 1a used for substitution. 
 
Demographics 
The final study’s sample consisted of 400 primary care physicians whose ages 
ranged from 27 to 88. The mean age was 48.7 (SD = 11.76).  The ages were collapsed 
into three groups (under 40, 40 to 50 years, over 50) for age comparisons.  There were 
286 (71.5%) males and 114 (28.5%) females that returned completed surveys (Table 17).   
                                       
                                        
 
 78
                                              Table 17 
     Final Study: Selected Demographic Characteristics of Responding Physicians 
 
Variable 
 
No. (n=400) 
 
% 
 
Current Age 
   Under 40 101 25.3 
   40-54 181 45.3 
   Over 55 118 29.5 
Gender 
   Male 286 71.5 
   Female 114 28.5 
Ethnicity 
   White 274 68.5 
   Black   11   2.8 
   Hispanic   42 10.5 
   Asian/Pacific Islander   67 16.8 
   Unknown     6   1.4 
Medical School 
   In-state 183 45.8 
   Out-of-state   99 24.7 
   Out-of-country 118 29.5 
Year of Graduation 
   1975 and later 129 32.3 
   1976-1989 158 39.5 
   1990 and earlier 113 28.3 
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The year of graduation from medical school ranged from 1940 to 2000.  The 
median year was 1982.  One hundred and eighty-three (45.8%) of the physicians attended 
a medical school in Texas, 99 (24.7%) attended an out-of-state medical school, and 118 
(29.5%) graduated from a medical school in another country.  One hundred and ninety-
two (48.0%) of the physicians identified their medical practice as private and 151 
(37.8%) as a group practice (Table 18).  Fifty-seven (14.3%) of the responding physicians 
reported something other than private or group.  In the final analysis, the physicians that 
reported they were affiliated with or worked in clinics, hospitals, or any other “group” 
atmosphere were aggregated with the group practice respondents.   
The physicians were asked which professional specialty best described their 
practice.  Ninety-five physicians (23.8%) reported their professional specialty as internal 
medicine, 96 (24%) pediatric, 57 (14.3%) obstetrics, gynecology, or obstetrics and 
gynecology, 95 (23.8%) family medicine, and 18 (4.5%) general practice.  Thirty-nine 
(9.8%) reported their specialty as something other than what was listed (Table 19).  The 
obstetrics, gynecology, and obstetrics and gynecology specialties were collapsed into one 
obstetrics/gynecology group for analysis.  
A proportional sample was randomly selected from each stratum (internal 
medicine, obstetrics and gynecology, pediatrics, family practice, general practice) using a 
table of random numbers.  The sampling fractions were combined to form an estimate for 
the population (see Table 16, page 74 in Methods).  For a population size of 21,306 
licensed primary care physicians as reported by the Texas State Board of Medical 
Examiners (December 2002), the study’s sample size of 400 (379, final + 21, pilot) was  
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Table 18 
Final Study: Practice Characteristics of Responding Physicians 
Practice Setting No. (n=400) % 
 
Private 
 
192 
 
48.0 
Group 151 37.8 
Other:   57 14.3 
   
 
 
 
 
 
 
 
 
Table 19 
Final Study: Professional Specialty of Responding Physicians 
Specialty No. (n=400) % 
 
Internal Medicine 
 
95 
 
23.8. 
Pediatrics 96 24.0 
Obstetrics and/or Gynecology 57 14.3 
Family Medicine 95 23.8 
General Practice 18   4.5 
Other: 39   9.8 
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sufficient to reach statistical representation for the population of primary care physicians 
in Texas.84  However, representation was not achieved for each individual specialty 
stratum, with the exception of the obstetrics/gynecology group (57 of 57 needed) and the 
pediatric group (96 of 76 needed) [Table 20]. 
 
 
Table 20 
Sample Size Needed and Obtained to Reach Representation for Each Specialty Stratum 
Specialty Needed     Obtained
 
Internal Medicine 
 
130 
 
     95 
Pediatrics  76      96 
Obstetrics and/or Gynecology  57      57 
Family Medicine 121      95 
General Practice   20      18 
Other    --      39 
    Total 404    400 
 
 
 
Of the 971 non-responders, 285 (29.4%) were female and 686 (70.6%) male.  The 
ethnicities of the non-responders as reported by the Texas Board of Medical 
Practitioner’s directory were 577 (59.0%) White, 59 (6.0%) Black, 137 (14.0%) 
Hispanic, 182 (19.0%) Asian, 1 (<1.0%) Indian, and 15 (2.0%) unknown.  There was no 
significant difference between the gender of responders and nonresponders [F(1,1369) = 
.000, p = .992.]  However, there was a difference between ethnicities of responders and 
nonresponders, [F(1,1369) = 12.79, p < .001.] 
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Descriptives for Criterion and Predictor Variables 
 
 The mean, standard deviation and possible range of scores for each of the study’s 
predictor variables – Relative Advantage, Compatibility (as indicated by compatibility 
with professional/personal beliefs and compatibility with current medical practice), 
Complexity, Trialability, Observability – and for the criterion variable (Likelihood of 
PCPs Adopting Genomic Medicine) are shown in Table 21.  A lower score for the 
predictor variable indicates a more positive perception of that characteristic of genomic 
medicine.  A lower score for the criterion variable indicates a higher likelihood of 
adopting genomic medicine. 
 
Table 21 
Mean, Standard Deviation, and Possible Range for Predictor and Criterion Variables 
Variables      n=400 Mean SD Possible Range 
Relative Advantage 21.24 13.06 (4-100) 
 
Professional and Personal 
beliefs 
 
18.13 
 
13.13 
 
(4-100) 
 
Current Practices 
 
23.43 
 
16.64 
 
(3-75) 
 
Complexity 
 
15.39 
 
10.37 
 
(2-50) 
 
Trialability 
 
10.55 
 
7.31 
 
(2-30) 
 
Observability 
 
23.79 
 
12.82 
 
(2-50) 
 
Likelihood to Adopt 17.10 3.70 (5-25) 
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A series of one-way ANOVAs performed between each of the predictor variables 
and selected demographic variables showed no significant differences among age groups, 
gender, and year of graduation or practice setting. 
 Tables 22-24 provide descriptive statistics for each of the items in the scales.  The 
mean and standard deviation for each item are for the sample as a whole.  The scores 
were collapsed into three categories of responses for the percentages.  The categories 
varied depending on the scale: 
• Agree, not sure, disagree 
• Important, not sure, not important 
• Already incorporated, agree, disagree 
• Easy, not sure, difficult 
• Already incorporated, likely, not likely 
Table 22 shows the majority of responders agreed that the selected clinical uses of 
genomic medicine were relative advantages.  “Supplementing a family history in 
predicting the risk of a healthy individual developing a disease” had the highest 
percentage (91.0%).  While the majority also agreed “diagnosing a genetic condition in 
an embryo before it is implanted” was an advantage of genomic medicine, this item had 
the lowest percentage of agreement (64.3%). 
On the compatibility scale, 60.5% responded that it was consistent with their 
professional beliefs to terminate a pregnancy when there is a substantial risk of a serious 
mental or physical abnormality (Table 23).  Only 56.5 % of the physicians, however, felt 
it was consistent with their personal beliefs.  “I don’t believe in abortions” was a written 
 
 Table 22 
Final Study:  Perceptions of the Relative Advantage of Genomic Medicine 
 
Strongly                    I’m not                          Strongly 
Agree         Agree        Sure        Disagree      Disagree 
   1               2            3                4                5 
 
  
      
      Mean              
 
 
       
     St.Dev. 
  
 
 
% who 
Agree 
                
% Not       % who 
Sure          Disagree 
 
1. I believe one of the advantages of genomic 
    genomic medicine is to… 
  a.  Diagnose a genetic condition in an embryo before it is 
       implanted instead of waiting and doing an ultrasound  
       later in the pregnancy. 
  b. Perform carrier testing for a possible autosomal 
       recessive disorder before the onset of symptoms. 
 
 
 
      2.47 
 
 
      1.88 
 
 
 
      1.28 
 
 
        .95 
 
 
 
  
 
 
 
64.3 
 
 
88.8 
 
 
 
13.3               22.5 
 
 
  3.0                 8.3  
  c.  Supplement a family history in predicting the risk 
       of a healthy individual developing a disease. 
      1.86         .94  91.0                  1.3                 7.8 
  d.  Supplement knowledge of previous medical history in  
       predicting which medications will be most effective 
       for specific patients. 
 
      2.11       1.18  
 
81.0   2.0                17.0 
Extremely    Somewhat      I’m not      Not Very      Not Important 
Important     Important       Sure           Important     At All 
      1                 2              3                   4              5 
 
2. How important is it for you to be able to… 
 
       Mean              
 
     St.Dev. 
  
 
     %  
Important 
% Not       % Not 
Sure          Important 
  a.  Detect a genetic condition in an embryo before 
       it is implanted? 
      2.62       1.38   55.3 18.8                26.0 
  b.  Test whether an individual possesses a copy of 
       a mutated gene for an autosomal recessive disorder before 
       the onset of symptoms? 
      2.10       1.18  
 
81.0   4.0                15.0 
  c.  Supplement a family history in predicting the risk of  
       a healthy individual developing a disease? 
      1.96       1.06  
  
87.0   3.0                10.0 
  d.  Supplement previous knowledge of medical history in 
       predicting which medications will be most effective for 
       specific patients? 
      2.06       1.20  
  
82.3   3.0                14.8 
Cronbach α .73 (8 items)  
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 Table 23 
Final Study:  Perceptions of the Compatibility of Genomic Medicine 
 
Strongly                    I’m not                          Strongly 
Agree         Agree        Sure        Disagree      Disagree 
   1               2            3                4                5 
 
  
      
      Mean              
 
 
       
     St.Dev. 
  
 
 
% who 
Agree 
                
  % Not       % who 
  Sure          Disagree 
 
3.  Termination of pregnancy when there is a substantial 
      risk that if a child were born it would suffer from a serious 
      mental or physical abnormality is consistent with my 
      professional beliefs. 
4.  Offering predictive testing for diseases in which there is no 
     available treatment or cure (such as Huntington’s Disease) 
      is consistent with my professional beliefs. 
 
      2.49 
 
 
       
      2.23 
 
      1.34 
 
 
        
      1.26 
 
 
 
  
 
60.5 
 
 
 
75.8 
 
  16.0               23.5 
 
 
   
    5.8               18.5 
5.  Termination of pregnancy when there is a substantial  
      risk that if a child were born it would suffer from a serious 
      mental or physical abnormality is compatible with my  
      personal values. 
6.  Predictive testing for diseases in which there is no available 
     treatment or cure (such as Huntington’s Disease) is 
     compatible with my  personal values.                    
      2.54 
 
 
 
      2.28 
      1.32 
 
 
 
      1.25 
 56.5    
 
 
 
73.8               
   22.5              21.0 
 
 
 
    7.8               18.5 
       
 
  
Extremely    Somewhat      I’m not      Not Very      Not Important 
Important     Important       Sure           Important     At All 
      1                 2              3                   4              5 
 
 
       Mean              
 
     St.Dev. 
  
 
     %  
Important 
% Not       % Not 
 Sure          Important 
  7.  How important is it to you for genomic medicine to be 
      consistent with your professional standards? 
  8.  How important is it to you for genomic medicine to be  
      compatible with your personal values? 
  9.  How important is it to you for genomic medicine to be 
      easily incorporated into your primary care practice? 
 
      1.69 
 
      2.07 
 
      2.29 
        .99 
 
      1.31 
 
      1.31 
  92.0 
 
82.5 
 
75.8 
   1.0                 7.0 
 
   1.5               16.0 
 
   3.8               20.5 
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 Table 23 continued 
 
Already              Strongly                                           Strongly 
Incorporated       Agree        Agree        Disagree      Disagree 
     1                    2               3                 4               5 
 
  
      
      Mean              
 
 
       
     St.Dev. 
  
 
 
% Already 
Incorporated 
                
% who       % who 
Agree         Disagree 
 
10.  Genetic counseling could easily be incorporated into 
        my primary care practice. 
11.  Taking a more detailed family history could easily 
        be incorporated into my primary care practice. 
12.  Genetic testing could easily be incorporated into 
        my practice. 
 
 
      3.41 
 
      3.02 
       
      3.41 
 
        .93 
 
        .88 
        
        .95 
 
 
 
  
 
 3.3 
 
 5.8 
 
 3.8 
 
48.3              48.5 
 
70.3              24.0 
   
48.0              48.3 
Cronbach α 
     Compatibility with professional/personal beliefs and values .65 (6 items) 
     Compatibiltiy with current medical practice .74 (4 items) 
 
 
 
 
 
 
 
 
 86
 
 Table 24 
Final Study:  Perceptions of the Complexity of Genomic Medicine 
 
Extremely    Somewhat    I’m not     Somewhat    Extremely 
Easy             Easy             Sure          Difficult       Difficult 
   1                 2               3                4                5 
 
  
      
      Mean              
 
 
       
     St.Dev. 
  
 
 
%  
Easy 
                
% Not       %  
Sure          Difficult 
 
13.  How easy or difficult is it for you to… 
 
   a.  Locate available genetic services? 
 
   b.  Stay updated on genomic-related knowledge? 
 
 
       
      3.00 
       
      3.68 
 
       
 
 
      
      1.50 
 
      1.37          
     
 
 
 
  
 
 
 
50.0 
 
28.3 
 
 
 
11.8            38.3 
 
17.5            54.3 
  
 
         
 
  
Extremely    Somewhat      I’m not      Not Very      Not Important 
Important     Important       Sure           Important     At All 
      1                 2              3                   4              5 
 
14. How important is it for you… 
 
 
       Mean              
 
     St.Dev. 
  
 
     %  
Important 
% Not       % Not 
Sure          Important 
  a.  To be able to locate available genetic services 
       without difficulty? 
 
      2.11       1.26   80.8   4.0                15.3 
  b.  To easily stay updated on genomic medicine-related 
        knowledge? 
      2.27       1.23  
 
79.8   3.0                17.3 
Cronbach α .60 (4 items) 
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comment on two of the surveys.  Another respondent wrote, “I disagree with the ethics of 
physicians who perform abortions.  However, I’d like to see genetics determined before 
sperm and egg unite as an embryo.” 
There was almost an even split between those who agreed that genetic counseling 
could easily be incorporated into primary care practice and those who disagreed (48.3% 
vs. 48.5%).  Results for the item regarding genetic testing were similar (48% vs. 48.3%).  
However, most of the respondents felt they could incorporate a more detailed family 
history into their practice (70.3%).  Over three percent are already doing some genetic 
counseling and 5.8% are already taking a more detailed family history.  Almost four 
percent have already ordered some type of genetic testing for their patients.  Half of the 
primary care physicians that responded to the survey found it easy to locate genetic 
services (Table 24).  Not surprisingly, 54.3% found it difficult to stay updated on 
genomic-related knowledge, yet most (79.8%) felt it was important to do so. 
The results of a one-way ANOVA revealed a significant difference between 
specialty groups and perceptions of the complexity of incorporating genomic medicine, 
[F (5,394) =16.481, p<.001].  The obstetrics/gynecology specialty group obtained scores 
that were significantly lower than all of the other groups except pediatrics (Table 25).  A 
lower score on this scale indicates that incorporating genomic medicine is perceived as 
less complex.  This suggests that physicians from the obstetrics/gynecology and pediatric 
specialties compared to the family medicine, general practice, internal medicine, and 
“other” specialties do not perceive genomic medicine to be as complex.
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Table 25 
Group Mean and Standard Deviation for Complexity of Genomic Medicine Scale 
Specialty   N Mean Std. Deviation 
Internal Medicine   95 17.29 10.06 
Pediatrics   96 10.75   7.77 
Obstetrics/Gynecology   57   8.95   5.36 
Family Medicine   95 19.71 10.89 
General Practice   18 19.17 11.43 
Other   39 19.43 12.37 
Total 400 15.40 10.37 
  
 
A Bonferroni post hoc analysis85 confirmed that the obstetrics/gynecology and pediatric 
groups did not differ from each other but did significantly differ from the other four 
specialty groups.  Cohen’s d (the difference between the means, divided by the pooled 
standard deviation) was calculated to determine the size of this difference.85 The 
magnitude in difference between the means of the obstetrics/gynecology group and the 
internal medicine, family medicine, general practice, and ‘other’ specialty group ranged 
from 0.49 to 1.27 standard deviations.  The magnitude in difference between the means 
of the pediatric group and the internal medicine, family medicine, general practice, and 
‘other’ specialty group ranged from 0.40 to 0.95 standard deviations.     
Seventy four percent of the respondents agreed that genetic services could be 
gradually incorporated into primary care practice (Table 26).  Over 60% felt it was 
important to gradually add genetic services and to try new technology before 
incorporating them into practice.  Results shown in Table 27 indicate that a greater 
percentage of physicians disagree that their colleagues are adopting genetic testing or  
 
 
  
Table 26 
Final Study:  Perceptions of the Trialability of Genomic Medicine 
 
Strongly                    I’m not                          Strongly 
Agree         Agree        Sure        Disagree      Disagree 
   1               2            3                4                5 
 
  
      
      Mean              
 
 
       
     St.Dev. 
  
 
 
% who 
Agree 
                
% Not       % who 
Sure          Disagree 
 
15.  Genetic services can gradually be incorporated into 
        primary care practice. 
   
 
      
       2.50 
      
      1.19 
 
 
 
 74.3 
  
 2.8                23.0 
Extremely    Somewhat      I’m not      Not Very      Not Important 
Important     Important       Sure           Important     At All 
      1                 2              3                   4              5 
 
17. How important is it for you to… 
 
       Mean              
 
     St.Dev. 
  
 
     %  
Important 
% Not       % Not 
Sure          Important 
  a.  To be able to gradually incorporate genetic services 
       into your practice? 
      2.85       1.42   61.3   6.3                32.5 
  b.  Incorporate technologies that you have tried first?       2.74       1.32  
 
64.8   5.0                30.3 
Cronbach α .65 (3 items) 
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Table 27 
Final Study:  Perceptions of the Observability of Genomic Medicine 
 
Strongly                    I’m not                          Strongly 
Agree         Agree        Sure        Disagree      Disagree 
   1               2            3                4                5 
 
  
      
      Mean              
 
 
       
     St.Dev. 
  
 
 
% who 
Agree 
                
% Not       % who 
Sure          Disagree 
 
18.  Most of my colleagues are… 
 
   a.  Adopting genetic testing into their practice. 
 
   b.  Assisting patients to make decisions regarding 
        genetic services. 
   
 
      
        
 
      3.86 
 
      3.37 
      
      
 
      1.18 
 
      1.30 
 
 
 
  
 
 17.5 
 
 36.5 
  
  
 
16.3                 66.3 
 
11.5                 52.0 
Extremely    Somewhat      I’m not      Not Very      Not Important 
Important     Important       Sure           Important     At All 
      1                 2              3                   4              5 
 
19.  Before you consider adopting genomic medicine 
       into your practice, how important is it for you 
      that your colleagues… 
 
 
       Mean              
 
     St.Dev. 
  
 
     %  
Important 
% Not       % Not 
Sure          Important 
  a.  Adopt genetic testing into their practice? 
 
  b.  Assist patients in making decisions regarding  
       genetic services? 
      3.35 
 
      3.08 
 
      
      1.41 
 
      1.45 
 
 
42.0 
 
51.5 
 
 
 13.5               44.5 
 
 10.3               38.3 
Cronbach α .60 (4 items) 
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assisting patients to make decisions regarding genetic services (66.3% and 52%, 
respectively).   
A between-subjects ANOVA was calculated with observability of genomic 
medicine as the dependent variable and specialty group (internal medicine, pediatrics, 
obstetrics/gynecology, family medicine, general practice, and other specialty) as the 
independent variables.  There was a significant effect of specialty group, [F (5,394) = 
4.39, p =. 001].  The Bonferroni post hoc analysis revealed that the internal medicine 
group (M = 28.0, SD = 13.18) and the obstetrics/gynecology group (M = 19.0, SD = 
12.79) were significantly different from each other (p<.001, Cohen’s d = 0.69) but not 
from the other groups.  A lower score indicates a stronger perception of the observability 
of genomic medicine.   In other words, the obstetrics/gynecology specialty group is 
observing their colleagues adopting genetic testing and assisting patients to make 
decisions regarding genetic services considerably more than the internal medicine 
specialty group.  The pediatrics (M = 22.7, SD = 11.84), family medicine (M = 23.4, SD 
= 12.74), general practice (M = 20.6, SD = 13.46), and ‘other’ (M = 25.8, SD = 11.39) 
specialty groups did not differ from each other. 
As shown in Table 28, the majority of the primary care physicians responded that 
they were likely to order carrier testing (55.5%), predictive testing (64.5%), and refer 
patients for a genetic consultation (80.5%).  Three percent, 1.5%, and 2.5%, 
respectively, are already doing so.  Almost 3% provide pre-conception counseling but 
the rest were split as to whether or not they are planning to incorporate this service (49% 
were likely to incorporate pre-conception counseling while 48.3% were not likely).  
  
Table 28 
Final Study:  Likelihood of PCPs Adopting Genomic Medicine 
 
I Already      Extremely   Somewhat    Not         Not Likely 
    Am           Likely          Likely          Likely     At All 
    1                2               3                 4             5 
 
  
      
      Mean              
 
 
       
     St.Dev. 
  
 
 
% Already 
Incorporated 
                
%              % Not  
Likely      Likely 
 
20.  For your patients, how likely are you to… 
 
   a.  Order carrier testing for a possible autosomal recessive 
        disorder? 
 
   b.  Order a preimplantation diagnosis to check for genetic 
      disease in an embryo? 
 
   c.  Order a predictive test for risk of disease? 
   
   d.  Provide pre-conception counseling? 
 
   e.  Refer them for a genetic consultation? 
 
       
 
      3.35 
 
       
      4.24 
       
       
      3.25 
 
      3.48 
 
      2.79 
 
         
 
        .99 
 
        
        .90 
        
         
         .94 
 
       1.14 
 
         .89 
 
 
 
  
 
 
 
  3.0 
 
  
  -- 
 
  
  1.5 
 
  2.8 
 
  2.5 
 
 
 
55.5              41.5 
 
 
20.5              79.5 
   
 
64.5              34.0 
 
49.0              48.3 
 
80.5              17.0 
Cronbach α .81 (5 items) 
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Eighty percent of the physicians responded that they were not likely to order 
preimplantation diagnosis and none were doing so at this time.  Table 29 shows the 
number of physicians by specialty that have already incorporated some type of genetic 
service into their practice.   
 
 
 
Table 29 
Physicians by Specialty Group Already Incorporating a Genetic Service 
Genetic Service   
n=400 
Internal       
Medicine 
Pediatrics Obstetrics/ 
Gynecology 
Family 
Medicine 
General 
Practice 
Other 
Specialty 
Tot 
 
 
Carrier testing 
 
1 
 
2 
 
8 
 
1 
 
0 
 
0 
 
12 
 
Preimplantation 
diagnosis 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
Predictive 
testing 
 
1 
 
1 
 
3 
 
 
1 
 
0 
 
0 
 
6 
 
Pre-conception 
counseling 
 
1 
 
3 
 
6 
 
1 
 
0 
 
0 
 
11 
 
Genetic 
referrals 
 
1 
 
2 
 
7 
 
0 
 
0 
 
0 
 
10 
 
          Total 
 
4 
 
8 
 
24 
 
3 
 
0 
 
0 
 
39 
 
 
A between-subjects ANOVA showed a significant effect of specialty group on 
Likelihood of PCPs Adopting Genomic Medicine, [F(5, 394) = 16.32, p<.001].  The  
obstetric/gynecology specialty scored significantly lower on the “Likelihood of PCPs 
Adopting Genomic Medicine” scale than the other groups.  A lower score on this scale 
indicates that this group is more likely to adopt genomic medicine than the other primary 
 95
 
care specialities (Table 30).  The mean-level difference between the obstetric and 
gynecology group and the other groups ranged from 0.53 to 1.31 standard deviations. 
 
 
Table 30 
Mean and Standard Deviation for Likelihood of PCPs Adopting Genomic Medicine 
Specialty   N Mean Std. Deviation 
Internal Medicine   95 18.27 3.62 
Pediatrics   96 16.56 2.71 
OB/GYN   57 13.84 3.10 
Family Medicine   95 17.53 3.70 
General Practice   18 17.78 3.41 
Other specialty   39 19.10 3.94 
Total 400 17.11 3.70 
A lower score indicates a stronger likelihood of adopting genomic medicine. 
Possible range = 5-25 
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Test for Linearity and Multicollinearity 
 
Pearson correlation measures the strength and direction of the linear relationship 
between the predictor and criterion variables.85  Most of the relationships were 
significant at the .05 and .01 level.  Table 31 shows that the criterion variable, 
Likelihood of PCPs Adopting Genomic Medicine, was linearly related to all of the 
variables in the model with the exception of the proposed moderator variable, 
Professional Practice (private or group practice) (r=.06).  Its strongest association was 
with Complexity (r=.46, p<.01), followed by compatibility with Current Medical 
Practice (r=.43, p<.01). 
  Linear associations were not observed between Professional Practice (private or 
group practice) and any of the other variables.  Excluding this proposed moderator 
variable (Professional Practice), all of the predictor variables had a significant linear 
relationship with the criterion variable and with each other.  Compatibility with 
Professional/Personal beliefs and Observability were the only other variables that were 
not related to each other (r=.01).  The variables Relative Advantage of genomic 
medicine and compatibility with Current Medical Practice had moderate associations 
with Complexity (r=.33, p<.01 and r=.41, p<.01).   
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Compatibility with Professional/Personal beliefs had a small association with 
compatibility with Current Medical Practice (r=.20, p<.01).  Complexity and Trialability 
of genomic medicine also had a small association with each other (r=.28, p<.01), as did 
Trialability and Observability of genomic medicine (r=.14, p<.01).  Overall results of 
this test of linearity show only small to moderate correlations among the independent 
variables, which reduced potential problems of multicollinearity in the regression and 
path analysis.     
 
 
Prediction of Likelihood of Primary Care Physicians’ Adopting Genomic Medicine 
 
 
The data were analyzed by multiple regression, using the dependent variable 
Likelihood of PCPs Adopting Genomic Medicine, all of the independent variables 
(Relative Advantage, Compatibility with Professional/Personal Beliefs and Values, 
Compatibility with Current Practice, Complexity, Trialability, and Observability), and 
the moderator variable Professional Practice (private or group practice) as predictors.   
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Table 31 
Pearson Zero-Order Correlations Among Predictor and Criterion Variables 
    Variables CV (Adopt) P1 P2 P3 P4 P5 P6
P1 Relative Advantage .337**       
 
P2 Compatibility with 
     Prof/Pers beliefs 
 
.170** 
 
.261** 
     
    
   
  
 
P3 Compatibility with 
     Current Med Practice 
 
.434** 
 
.295** 
 
.205** 
 
P4 Complexity 
 
.463** 
 
.330** 
 
.114* 
 
.415** 
 
P5 Trialability 
 
.270** 
 
.156** 
 
.136** 
 
.361** 
 
.287** 
 
P6 Observability 
 
.282** 
 
.170** 
 
 .011 
 
.259** 
 
.192** 
 
.148** 
 
 
P7 Professional Practice 
 
.060 
 
.000 
 
-.012 
 
.002 
 
.022 
 
-.029 
 
-.003 
  *p<.05 
**p<.01 
CV = Criterion Variable  
P1-P7 = Predictor Variables 
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Table 32 presents a series of regression models estimating the net effects of 
demographic variables, perceived characteristics of genomic medicine and professional 
practice (private or group).  In Model 1, Likelihood of Adopting Genomic Medicine is 
considered s a function of socio-demographic factors.  In model 2, Relative Advantage 
was added as a predictor.  Model 3 includes Compatibility with Professional/Personal 
beliefs and values and Compatibility with Current Practice as predictors.  In Model 4 
Complexity was added as a predictor, Trialability in Model 5, Observability in Model 6, 
and Professional Practice in Model 7. 
 None of the socio-demographic variables are significant predictors of Likelihood 
to Adopt Genomic Medicine.  Four of the perceived characteristics of genomic medicine 
(Relative Advantage, Compatibility with Current Practice, Complexity, Observability) 
are associated with Likelihood to Adopt Genomic Medicine.  For Models 4, 5, 6, and 7, 
Complexity was shown to be the strongest predictor of Likelihood to Adopt Genomic 
medicine.  The effect of the Complexity variable is affected very little by the inclusion 
of the other variables in the model (Table 32). 
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Table 32  
 Metric and Standardized Beta Coefficients for Predictors of Likelihood of PCPs Adopting Genomic Medicine, 
According to Different Regression Models 
 
Predictors 
Model 1 
Adj R2 = -.005 
B                β 
Model 2 
Adj R2 = .104 
B                  β 
Model 3 
Adj R2= .224 
B                  β 
Model 4 
Adj R2= .295 
B                   β 
Model 5 
Adj R2= .299 
B                   β 
Model 6 
Adj R2= .314 
B                   β 
Model 7 
Adj R2=.317 
B                    β 
Constant -5.815            
(100.17) 
18.330 
(94.61) 
-6.764 
(88.19) 
-17.144 
(84.06) 
-15.828     
(83.86) 
-6.093        
(83.00) 
-7.756          
(82.82) 
Gender   -.419          -.051 
  (.432) 
  -.398            -.049 
  (.408) 
-.387            -.047  
(.380) 
  -198            -.024 
(.363) 
-.271              -.037 
(.365) 
-.195              -.024        
(.362) 
-228               -.028 
(.362) 
Age -2.052E-03  -.007 
  (.051) 
-9.582E-04   - .003 
  (.048) 
7.407E-03     .024 
  (.045) 
1.712E-02      .054 
 (.043) 
1.472E-02      .058 
(.043) 
1.406E-02       .045 
(.043) 
1.760E-02      .056 
(.042) 
Graduation  
year 
1.169E-02     .038 
  (.049) 
-1.543E-03   -.005  
  (.047) 
1.039E-02     .034 
 (.043) 
1.507E-02      .049 
 (.041) 
1.443E-02      .049 
(.041) 
9.075E-02       .030 
(.041) 
9.539E-02       .031 
(.041) 
Ethnicity -8.014E-03  -.002 
  (.165) 
1.046E-02      .003 
  (.156) 
4.352E-02     .014 
 (.146) 
-4.338E-02   .-014 
 (.139) 
-6.446E-02   -.016 
(.140) 
-5.265E-02    -.016 
(.138) 
-3.907E-02     -.012 
(.138) 
Specialty    .146            .062 
  (.119) 
8.974E-02      .038 
  (.113) 
-3.057E-02   -.013 
 (.106) 
-.104             -.044 
 (.102) 
-.105             -.045 
(.102) 
-6.237E-02    -.027 
(.102) 
-6.218E-02     -.026 
(.101) 
Relative 
Advantage 
    .107         .336*** 
  (.015) 
7.029E-02   .222*** 
 (.015) 
4.810E-02   .152** 
 (.015) 
4.783E-02   .156** 
(.015) 
4.411E-02    .139** 
(.015) 
4.568E-02     .144** 
(.015) 
Compatibility 
 with Current 
Practice 
  8.082E-02   363*** 
 (.011) 
5.752E-02  .258*** 
 (.011) 
5.257E-02  .233*** 
(.011) 
4.601E-02    .207*** 
(.011) 
40530E-02    .204*** 
(.011) 
Compatibility  
with Profess/ 
Personal 
beliefs 
  1.476E-02     .035 
 (.019) 
1.815E-02     .044 
 (.018) 
1.634E-02     .037 
(.018) 
2.078E-02     .050 
(.018) 
1.979E-02       .048 
(.018) 
Complexity     .110          .308*** 
 (.017) 
.105           .289*** 
(.017) 
 .101            .284*** 
(.017) 
9.953E-02    ..279*** 
(.017) 
Trialability     3.980E-02    .083 
(.023) 
3.534E-02     .070 
(.023) 
3.735E-02      .074 
(023) 
Observability          3.973E-02 .138** 3.937E-02    .136** 
(.013) (.013) 
Professional 
Practice 
      .362                .070 
(.219) 
* p<.05     ** p<.01    *** p<.001 
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Structural Equation Model 
 
The Analysis of MOment Structures (AMOS 4.0) structural equation modeling 
software was also used for analysis and for testing the proposed model’s fit to the data.  
Structural equation modeling (SEM) determines whether the model’s implied covariance 
matrix of the measures is consistent with an empirical or data-based covariance matrix.86  
The technique also evaluates the contribution of each of the independent variables to the 
dependent variables.85  Like multiple regression, the goal may be to predict which 
independent variable has the strongest influence on the dependent variable.  Some of the 
variables can be latent, whereas others are directly observed.  SEM assumes that all the 
relations are linear and that the underlying measurement and latent variables are 
continuous.87    
The model for this study was comprised of Relative Advantage, Compatibility, a 
latent variable with 2 indicators (Compatibility with Professional/Personal Beliefs and 
Values and Compatibility with Current Practice), Complexity, Trailability, 
Observability, and Likelihood of PCPs Adopting Genomic Medicine (Figure 8).  The 
model Chi Square value, also called discrepancy, represents the result of testing whether 
the implied variance structure is different from the observed (or measured) covariance 
matrix.  Ideally, the two covariance matrices are the same (do not differ) and represent, 
therefore, a “good fit” for the model to the measured data.  When interpreting results, 
therefore, researchers hope for a non-significant finding for the Chi-Square value.  A 
statistically significant finding indicates that the two matrices/models differ substantially 
enough to indicate a “poor fit.”  In other words, a finding of significance means the 
  
                                                         
                                                   Perceived Characteristics of Genomic Medicine 
                                                                     Expectations/Expectancies 
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                                       .09                                                                                                                
                                                                                                                               .15 
                                                         .29 
 
                                                                                                                     .34                                           .26 
                                      .48              .70 
 
 
                                                                                                                      .31 
 
 
 
                                                                                                                    .07 
                                                                                                                    
 
                                                                                                                    .15 
                                                                                                                     
Complexity 
Trialability 
Observability 
 
Compatibility
Personal/Professional 
   beliefs and values 
Current Medical 
Practices 
Relative Advantage
Likelihood of 
PCPs Adopting 
Genomic Medicine
 
 
 
 
X2 = 258.59, df = 14, p = 0.000, RMSEA = 0.64 
 
Figure 8   Structural Equation Model for the Whole Sample 
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given model’s covariance structure is significantly different from the observed 
covariance matrix.88  The Chi Square for the model tested in this study showed that the 
overall fit of the proposed model was poor, X2 = 258.59, df 14, p = 0.000.  The root 
mean square error of approximation (RMSEA) is a measure of discrepancy per degree of 
freedom between the model and the population.  A RMSEA of 0.05 or lower indicates a 
close fit.88  The RMSEA of the proposed model was 0.64 further supporting the model’s 
lack of fit.  The model explained only 26% of the variance for likelihood of PCPs 
adopting genomic medicine.  A nested model comparison for the two separate groups – 
private practice, group practice – was also calculated.  The analysis revealed an equally 
poor fit for both groups.  
 Both the regression models and the SEM indicate that other factors must be 
measured when attempting to fully understand PCPs likelihood of adopting genomic 
medicine, such as insurance coverage, ethical, and political issues. 
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CHAPTER V 
CONCLUSION, LIMITATIONS, AND DISCUSSION 
 
 
Conclusion 
It has been predicted that genomic medicine will change the future of health care.  
Achievements of the Human Genome Project are helping to identify the genes that 
contribute to common disorders such as diabetes, breast cancer, Alzheimer’s, and cancer 
as well as genetic variants that influence a patient’s response to a particular drug.67,3,89  It 
has been projected that primary care physicians (PCPs) will play a larger role in 
predispositional diagnosis and management of many common disorders.  These 
physicians will be using genetic testing routinely to determine the disorders their patients 
will someday develop.90   
Clinical applications of genomic medicine will be adopted by PCPs at a variable 
pace.  Characteristics of an innovation such as genomic medicine are strong indicators of 
its potential for adoption.  Everett M. Roger’s11 Diffusion of Innovations theory defines 
an innovation as an idea, practice, or object that is perceived as new by members of a 
social system.  According to Rogers, there are five characteristics of an innovation that 
influence the rate of its adoption; the relative advantage of the innovation, its 
compatibility, complexity, trialability and observability.  The purpose of this study was 
to assess whether (and to what extent) physicians’ perceptions of genomic medicine as 
an innovation influence their likelihood of adopting this innovation into primary care.    
Findings from this study indicate that the Texas PCP who is most willing to 
adopt genomic medicine into his/her practice, strongly believes that genomic medicine 
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provides important advantages over traditional forms of medical practice, strongly 
perceives genomic medicine to be consistent with his/her professional and personal 
beliefs and values, and strongly perceives genomic medicine as a not-so-complex 
innovation.  Additionally, the practitioner willing to adopt genomic medicine does not 
consider it very important to observe most of his or her colleagues adopting genomic 
medicine before considering adopting this innovation him/herself.  These findings lend 
further support for the Diffusion of Innovations theory, which states that “innovators” 
require shorter adoption periods, have the ability to cope with a high degree of 
uncertainty about the innovation and the ability to understand and apply complex 
technical knowledge.75 One of the responders commented on his/her survey: “I strongly 
believe genomic medicine will change the future of medicine.  Treatment will change in 
the next five years from treating the patient after the disease to prevention of disease 
with genetic engineering.”   
The degree to which an innovation is perceived as better than what is presently 
being practiced can influence the rate of adoption.11 According to this study, Texas 
primary care physicians believe one of the best advantages of genomic medicine is to 
supplement a family history.  They also feel that taking a more detailed family history 
could easily be incorporated into their primary care practice.  Khoury91 maintains that a 
good “family history can build a bridge from genetics to genomics in practice.”(p265)  
Previous family history can predict the risk factor for most chronic diseases such as 
coronary heart disease, diabetes, cancer, osteorporosis, and asthma.  Yet family history is 
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rarely used in preventive medicine to assess disease risk or influence early detection and 
motivate prevention strategies.91 
Wilkins-Haug and colleagues92 found that gynecologists who take family 
histories to perform preconception screening also use that information to screen for 
increased risk of breast cancer, ovarian cancer, other cancers, and certain adult-onset 
disorders.  However, only a small percentage of their respondents ordered DNA-based 
genetic tests to screen for disease even though they had patients who requested the tests.   
In order for an innovation to be adopted it must be consistent with existing 
values, beliefs, and present practices of potential adopters.11 Findings from this study 
indicate that offering termination of a pregnancy as an option even if the child would 
suffer from a severe mental or physical abnormality is not consistent with many Texas 
PCPs personal beliefs and values.  Prenatal diagnosis and termination of pregnancy 
raises important ethical dilemmas when diagnosis and prognosis are uncertain.  Deciding 
what is considered “severely abnormal” can cross that fine line to eugenics.
This study also found that although Texas PCPs perceive clinical applications of 
genomic medicine to be consistent with professional standards, components such as 
ordering genetic testing and genetic counseling are not compatible with their current 
practice.  Genetic counseling is usually provided by physicians or counselors with 
advanced training in genetics.93  Integrating this genetic service into practice requires 
additional time to interpret information about genetic disorders, analyze inheritance 
patterns and risks of recurrence, review available options with the patient’s family and 
refer individuals and families to community or state-supported services.94  
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The anticipated explosion in genetic information will be a challenge for genetic 
counseling, no matter who provides it.93 The more difficult it is to understand and use an 
innovation, the more reluctant potential adopters will be to embrace the change.70  It was 
not a surprise that many Texas PCPs in this study find it difficult to stay updated on 
genomic-related knowledge.  Many studies have identified inadequate knowledge of 
genetics, genetic testing, or genetic counseling as a barrier to incorporating genetic 
services in primary care.34,35,95,96,97,98,99,100  In the study reported here, the 
obstetrics/gynecology and pediatric specialty group perceive genomic medicine to be 
less complex than the other specialty groups.  The data suggest that the family medicine 
specialty group perceived genomic medicine to be more complex than the other specialty 
groups.  Fetters and colleagues101 found that many family medicine physicians feel there 
have been inadequate education opportunities to learn about genetics, genetic 
counseling, and the Human Genome Project.  However, many of these physicians also 
indicated reluctance to invest in self-educational efforts until genetic problems become 
more relevant to their patients.  
Texas PCPs in this study feel that genetic services could be incorporated into 
primary care practice on a gradual basis. Physicians are more likely to adopt an 
innovation if it is easy to try without having to fully commit to it or give up an existing 
practice.   Considerable uncertainty exists about the purpose and value of genomic 
medicine as well as the evaluation and consequences of its use.14 Trying out an 
innovation or new technology allows potential adopters to reduce their uncertainty about 
its risks and benefits.14   
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Applications of genomic medicine lack immediate visible results and are 
therefore not very observable.  For example, a change in lifestyle may improve the long-
term health outcome of a patient found to be susceptible to Type II diabetes but show no 
immediate changes in health.  “The willingness of physicians to offer an accurate, low-
cost test to predict future disease, even if no others in their specialty do, has implications 
for the diffusion of new genetic technology, at least in the initial stages.”102 (p1000)  With 
the exception of the obstetric/gynecology specialty, most of the respondents in the 
present study were not currently observing colleagues adopting genetic services or 
assisting patients to make decisions regarding genetic services.  
 
Likelihood of PCPs Adopting Genomic Medicine 
Texas primary care physicians in this study were likely to order carrier testing 
(55.5%), to order predictive testing (64.5%), and to refer patients for a genetic 
consultation (80.5%).  Almost half (49%) were likely to order preconception counseling.  
The present study found that the obstetrics/gynecology specialty group was more likely 
than the other specialty groups to adopt all clinical uses of genomic medicine.  Although 
PCPs in all specialty groups (internal medicine, pediatrics, obstetrics/gynecology, family 
medicine, general practice, other specialty) felt an advantage of genomic medicine is to 
diagnose a genetic condition in an embryo before it is implanted, only 20.5% (mostly 
obstetrics and gynecology PCPs) were likely to order preimplantion diagnosis for their 
patients.   
Preimplantation genetic diagnosis (PGD) is offered as an alternative to prenatal 
diagnosis to avoid the risk for pregnancy termination.103   PGD is presently applicable 
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for numerous genetic-related disorders.  For example, PGD has been performed for 
couples carrying gene mutations known to determine a strong predisposition to most 
cancers.  Applications of this genetic technology has also been indicated for 
neurofibromatosis, a common autosomal-dominant neurological disorder, as well as 
early-onset Alzheimer’s disease, an autosomal dominant familial predisposition to 
presenile dementia.103 
A PGD-assisted pregnancy can ensure that the resulting baby is human leukocyte 
antigen (HLA)-matched to an affected sibling in need of a bone marrow 
transplantation.103 However, both stem cell research and preimplantation diagnosis are 
entangled in the debate over abortion, and the general question of when human life 
begins.  Another controversial use of preimplantation diagnosis involves identifying and 
choosing gender for non-therapeutic purposes.  This practice is considered 
discriminatory and not in the best interest of society nor for the resulting child.45  
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Limitations 
 
While this study examined a randomly selected sample of primary care 
physicians in the state of Texas, one of its limitations is the possibility that physicians 
responding to the survey had more genetics knowledge or stronger interest in genomic 
medicine than the nonresponders.  Because of the significant difference between the 
ethnicities of the responders and nonresponders, this study is also limited in its capability 
to generalize across all ethnicities of primary care physicians.  A comparison of the total 
random sample (1371) showed Black responders to be significantly underrepresented 
(5.0%) when compared to White (33.8%), Hispanic (22%), and Asian (24%) responders. 
The model proposed for this study only accounted for 26% of the variance in the 
structural equation analysis of likelihood of primary care physicians adopting genomic 
medicine (and 32% in the multiple regression model containing all proposed variables.)  
Since it was necessary to keep the survey brief, this study only examined the perceived 
characteristics of the innovation of genomic medicine.  Rates of diffusion and adoption 
depend to a large extent on how certain characteristics of the innovation interact with the 
targeted social system.  Because the behaviors or characteristics of the system’s 
individual members (i.e., perceived norms, personal innovativeness) also are crucial for 
understanding the adoption process,70 future research is needed to examine the 
characteristics of the “innovators,” which may account for a larger portion of the 
variance in the likelihood of adoption of genomic medicine.  Previous studies found that 
“early adopters” or “innovators” are able to cope with a high degree of uncertainty about 
an innovative technology such as genomic medicine.102   
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An interesting finding in this study was that Texas PCPs are similar in their 
perceptions about genomic medicine regardless of their practice setting (group, private.)  
However, the choice of practice setting (private or group) as a possible moderator 
variable proved to be a weakness for the study’s proposed model.  Data analysis showed 
that the social system that actually had the most effect on the other variables was the 
specialty group (internal medicine, pediatric, obstetrics/gynecology, family medicine, 
general practice, or other specialty.)   However, use of “specialty group” as a moderator 
variable to examine nested models was not included in the structural equation analysis 
due to the insufficient numbers in each group’s sample. Other characteristics of the 
primary care physician’s social network (e.g., managed care organizations, government 
institutions) as well as their communication channels (journals, professional societies 
and conferences) also need to be considered in the adoption and diffusion of genomic 
medicine.   
Moreover, the ethical, legal, and social issues of genomic medicine as well as the 
funding of genetic services were not explored in this study.  However, comments from 
several respondents made it clear that these characteristics of genomic medicine cannot 
be overlooked in the adoption and diffusion process: 
HMO/PPO either won’t pay [for genetic services] or for sure do not pay for the 
time it takes to do this.  The real world of medicine isn’t very good!   
 
Providing genetic services is a time consuming practice with low 
reimbursements.  Also border town issues such as no insurance coverage. 
 
[Genetic services are] usually driven by insurance provider contracts. 
 
If I get reimbursed by insurance companies for the time I will spend doing all 
these [genetic services], I will be happy to do so. 
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Discussion 
The transition from traditional medicine to genomic medicine will require most 
PCPs to understand the language of the “new genetics”95 and receive ongoing support to 
communicate effectively with patients and their families.  Mann104 calls for a new model 
of health care to be developed incorporating PCPs, specialists, and allied health care 
professionals in order to provide relevant genetic information and procedures to the 
patients and community.  As primary care becomes more focused on prevention, the 
future of health care also will need to include the health promotion specialist.  For 
Guttmacher,105 “Health educators will play a key role in shaping messages about 
individualized health maintenance that will be critical to the full flowering of genomic 
health care.” (p220)   
Nevertheless the emphasis on concepts of risk and disease predisposition will be 
a challenge for health educators.  While clinical genetic specialists are experienced in 
patient education, health educators have more experience in affecting health 
behaviors.106  Much of the power of genomic medicine will rely on the ability to change 
behaviors (including lifestyle and diet) based upon predisposition for health risks.105
Caumartin and colleagues107 call for students of all disciplines to add to their discipline-
specific skills an understanding of the role genetics will play.  The authors add that for 
health behavior/health education specialists, genetic roles may include:107 
• Assessing public demand for genetic information. 
• Educating the public on genetic issues. 
• Evaluating the psychosocial impact of this information on individuals, 
families, and populations. 
• Developing educational strategies that will communicate the 
complexities of genetics to the lay public. 
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• Developing effective behavior modifications that prevent disease in those 
with an inherited susceptibility.  The goal will be to assist the public in 
making reasoned decisions about their use of genetic testing, 
understanding test results, and analyzing the impact that test results may 
have on their lives.   
• Contributing to an understanding of individual variation in the utilization 
of genetic services.   
• Taking a key role in defining the ethical and social dimensions and 
implications of genetic technology. 
 
The impact of genetics on health care delivery and training, and on the role of 
primary care physicians provides a major challenge for those charged with promoting 
new genetic technologies.  There is a legitimate need to control genetic technology 
diffusion while research is conducted to assess clinical utility and cost effectiveness 
(versus pressures for adoption created by the media), public demand, producers and the 
profession.108 
“It is clear that both the public and health professionals dealing with the public 
need further education regarding the role of genetics in health and disease.”106 (p90) As 
Guttmacher105 highlights, however, “the expansion of nongenetic specialist providers’ 
use of genetics will not relegate genetic specialists to the dustbin of medical history, but 
instead will redefine their roles.”(p218)  The diagnosis and long-term follow-up of  
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individuals with monogenic and chromosomal conditions will continue to require the 
specialized knowledge that remains part of the genetic specialist’s practice.105 
As genetic information becomes more relevant to common disorders, PCPs will 
perceive an expanded role for themselves in genomic medicine such as evaluating 
genetic risk, counseling patients about testing, ordering tests, and referring patients for 
genetic consultation.109 The present study indicates that greater emphasis will need to be 
placed on knowledge pertinent to genomic medicine in medical education curricula.  It 
will also be important for continuing education programs to be developed and offered to 
primary care physicians to keep them updated on new advances in genomic medicine as 
well as information regarding genetic services in their area.  Burke and Emery43 assert 
that relevant genetics education for primary care would include information about the 
indicators of genetic disease and the rationale for including genetic disorders in the 
differential diagnosis of common problems.   For the already time-constrained physician, 
sources for quick reference when a patient presents with an unusual clinical problem or 
family history would also be helpful.  
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Test Results, Positive 
There is no magic in my bag 
No aces up these white coat sleeves 
No healing spells, no tricks to please 
No Merlin’s song to save the day. 
 
To comfort you should be my trick 
Should be our goal, our common boast. 
To do no harm, my solemn oath 
Is jeopardized by what I know. 
 
The words I chant will shake your soul 
Will bubble forth to change your life 
Like sorcerers with beards of white 
Will make you yearn for days gone by. 
 
The news I bring is from the void. 
It summons grief, directs the storms. 
A crimson cape of life’s dreams torn 
This wizard waves before your eyes. 
 
I mix my brew, you toss it down. 
The genie’s out, the truth is loose, 
Your perfect health: a painful ruse. 
No magic words will save you now. 
 
  By J. Trig Brown, M.D.110 
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GLOSSARY OF GENETIC TERMS 
 
 
   
Alzheimer's Disease 
 
This is the most common cause of dementia in those over 65.  The condition is more 
common in women.  The disease usually presents with memory loss and a gradual 
progressive deterioration in functioning 
 
Amniocentesis
Prenatal diagnosis method using cells in the amniotic fluid to determine the number and 
kind of chromosomes of the fetus and, when indicated, perform biochemical studies.  
 
Autosomal Recessive Gene  
A gene which will be expressed only if there are 2 identical copies or, for a male, if one 
copy is present on the X chromosome.  
 
BRCA1/BRCA2 
The first breast cancer genes to be identified. Mutated forms of these genes are believed 
to be responsible for about half the cases of inherited breast cancer, especially those that 
occur in younger women. Both are tumor suppressor genes. 
 
Carrier -- an individual heterozygous for a single recessive gene.  
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Carrier Testing 
Carrier testing is performed to identify individuals who have a gene mutation for a 
disorder inherited in an autosomal recessive or X-linked recessive manner. Carriers 
usually do not themselves have symptoms related to the gene mutation. Carrier testing is 
offered to individuals who have family members with a genetic condition, family 
members of an identified carrier, and individuals in ethnic or racial groups known to 
have a higher carrier rate for a particular condition. 
 
Chromosome -- in the eukaryotic nucleus, one of the threadlike structures consisting of 
chromatin and carry genetic information arranged in a linear sequence.  
 
Chorionic Villus Sampling
An invasive prenatal diagnostic procedure involving removal of villi from the human 
chorion to obtain chromosomes and cell products for diagnosis of disorders in the human 
embryo.  
   
Cystic Fibrosis  
An autosomal recessive genetic condition of the exocrine glands, which causes the body 
to produce excessively thick, sticky mucus that clogs the lungs and pancreas, interfering 
with breathing and digestion.  
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Disease -- any deviation from the normal structure or function of any part, organ, or 
system of the body that is manifested by a characteristic set of symptoms and signs 
whose pathology and prognosis may be known or unknown.  
 
 Diabetes Millenitis  
Two types of a highly variable disorder in which abnormalities in the ability to make 
and/or use the hormone insulin interfere with the process of turning dietary 
carbohydrates into glucose, the body's fuel. Type I is known as insulin dependent 
diabetes mellitus, and type II is known as non-insulin dependent diabetes mellitus. 
 
Diagnostic Testing 
Diagnostic testing is used to confirm or rule out a known or suspected genetic disorder in 
a symptomatic individual. 
 
Double Helix 
The structural arrangement of DNA, which looks something like an immensely long 
ladder twisted into a helix, or coil. The sides of the "ladder" are formed by a backbone of 
sugar and phosphate molecules, and the "rungs" consist of nucleotide bases joined 
weakly in the middle by hydrogen bonds. 
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DNA Sequencing
"Plus and minus" or "primed synthesis" method, developed by Sanger, DNA is 
synthesized in vitro in such a way that it is radioactively labeled and the reaction 
terminates specifically at the position corresponding to a given base; the "chemical" 
method, ssDNA is subjected to several chemical cleavage protocols that selectively 
make breaks on one side of a particular base.  
   
Down Syndrome  
A type of mental deficiency due to trisomy (three copies) of autosome 21, a translocation 
of 21 or mosaicism.  
   
Duchenne/Becker Muscular Dystrophy
The most common and severe form of muscular dystrophy; transmitted as an X-linked 
trait. X-linked recessive. Symptoms include onset at 2-5 years with difficulty with gait 
and stairs, enlarged calf muscles, progression to wheelchair by adolescence, shortened 
life span.  
   
ELSI
Ethical, legal and social implications (of HGP).  
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Ethics 
The study of fundamental principles which defines values and determines moral duty 
and obligation.  
   
Eugenics  
The improvement of humanity by altering its genetic composition by encouraging 
breeding of those presumed to have desirable genes.  
   
Fragile-X Syndrome 
X-linked trait; the second most common identifiable cause of genetic mental deficiency.  
   
Gene 
A hereditary unit that occupies a certain position on a chromosome; a unit that has one 
or more specific effects on the phenotype, and can mutate to various allelic forms.  
 
Gene Therapy  
Addition of a functional gene or group of genes to a cell by gene insertion to correct an 
hereditary disease.  
 
Genetic Counseling  
The educational process that helps individuals, couples, or families to understand genetic 
information and issues that may have an impact on them.  
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Genetic Screening 
Testing groups of individuals to identify defective genes capable of causing hereditary 
conditions.  
   
Genetic Variation 
A phenotypic variance of a trait in a population attributed to genetic heterogeneity.  
   
Genetics  
The study of inheritance patterns of specific traits.  
 
Genome  
All the genetic material in the chromosomes of a particular organism; its size is 
generally given as its total number of base pairs.  
 
Genomics  
The study of genes and their function.  
 
Hemochromatosis 
The most common form of iron overload disease, is an inherited disorder that causes the 
body to absorb and store too much iron. The extra iron builds up in organs and damages 
them. Without treatment, the disease can cause these organs to fail. 
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Hemoglobin Disorder   
Hemoglobin is a respiratory protein contained in red blood cells that transports oxygen 
from the lungs to the tissues of the body.  A Hemoglobin disorder is a condition caused 
by a defect in the genetic code for hemoglobin synthesis. This defect affects the amount 
or the quality of the hemoglobin being produced. Sickle cell anemia is a common 
hemoglobin disorder.  Other common hemoglobin disorders include hemoglobin SC 
disease and S-beta thalassemia. 
 
Hemophilia 
The hemophilias are inherited disorders that cause abnormal bleeding. Symptoms range 
from increased bleeding after trauma, injury, or surgery to sudden bleeding with no 
apparent cause. The two types of hemophilia are hemophilia A (also called classic 
hemophilia) and hemophilia B (also called Christmas disease). Hemophilia A is more 
common -- about 85% of people who have hemophilia have this form.  
 
Human Leukocyte Antigen (HLA)  
Proteins located on the surface of white blood cells which play an important role in our 
body's immune response to foreign substances. These antigens are also used to determine 
the suitability of a match between an donor and a recipient. Patients and potential donors 
have their white blood cells tested for three antigens - HLA-A, -B and -DR. Each 
individual has two sets of these antigens, one set inherited from each parent. For this 
reason, it is much more likely for a brother or sister to match the patient than an 
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unrelated individual, and much more likely for persons of the same racial and ethnic 
backgrounds to match each other.  
 
 
Human Genome Project 
The joint national effort, led by DOE and NIH,  begun in 1986 by DOE to create an 
ordered set of DNA segments from known chromosomal locations, develop new 
computational methods for analyzing genetic map and DNA sequence data, and develop 
new techniques and instruments for detecting and analyzing DNA.  
 
Huntington Disease 
A disease characterized by irregular, spasmodic involuntary movements of the limbs and 
facial muscles, mental deterioration and death, usually within 20 years of the onset of 
symptoms.  
 
Marfan Syndrome -- autosomal dominant condition of connective tissue; affects the 
skeletal, ocular and cardiovascular systems.  
 
Mendelian Inheritance  
One method in which genetic traits are passed from parents to offspring. Named for 
Gregor Mendel, who first studied and recognized the existence of genes and this method 
of inheritance.  
 
 134
 
Monogenic 
A disorder caused by mutation of a single gene. 
 
Multifactorial 
A characteristic influenced in its expression by many factors, both genetic and 
environmental.  
   
Mutation 
Process by which genes undergo a structural change.  
Neurofibromatosis  
One of the most common single gene conditions affecting the human nervous system; in 
most cases, "cafe au lait" spots, are the only symptom; inherited as an autosomal 
dominant trait, with 50% being new mutations.  
 
Newborn Screening 
Newborn screening identifies individuals who have an increased chance of having a 
specific genetic disorder so that treatment can be started as soon as possible.  
Points to consider: 
◊ Newborn screening programs are usually legally mandated and vary from state to 
state.  
◊ Newborn screening is performed routinely at birth, unless specifically refused by 
the parents in writing.  
◊ Screening tests are not designed to be diagnostic, but to identify individuals who 
may be candidates for further diagnostic tests. 
◊ Many parents do not realize that newborn screening has been done (or which 
tests were included), even if they signed a consent form when their child was 
born.  
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◊ Education is necessary with positive screening results in order to avoid 
misunderstandings, anxiety and discrimination.  
 
 
Pharmacogenomics  
The study of the interaction of an individual's genetic makeup and response to a drug.  
 
Polygenic Disorder  
Genetic disorder resulting from the combined action of alleles of more than one gene 
(e.g., heart disease, diabetes, and some cancers). Although such disorders are inherited, 
they depend on the simultaneous presence of several alleles; thus the hereditary patterns 
usually are more complex than those of single-gene disorders.  
 
Predictive Testing 
Predictive testing is offered to asymptomatic individuals with a family history of a 
genetic disorder. Predictive testing is of two types: presymptomatic (eventual 
development of symptoms is certain when the gene mutation is present, e.g., Huntington 
disease) and predispositional (eventual development of symptoms is likely but not 
certain when the gene mutation is present, e.g., breast cancer).  
 
Predisposition -- to have a tendency or inclination towards something in advance.  
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Preimplantation Testing (Preimplantation Genetic Diagnosis)  
Preimplantation testing is performed on early embryos resulting from in vitro 
fertilization in order to decrease the chance of a particular genetic condition occurring in 
the fetus. It is generally offered to couples with a high chance of having a child with a 
serious disorder. Preimplantation testing provides an alternative to prenatal diagnosis 
and termination of affected pregnancies. 
 
Prenatal Testing 
Prenatal testing is performed during a pregnancy to assess the health status of a fetus. 
Prenatal diagnostic tests are offered when there is an increased risk of having a child 
with a genetic condition due to maternal age, family history, ethnicity, or a suggestive 
fetal ultrasound examination. Routine prenatal diagnostic test procedures are 
amniocentesis and chorionic villus sampling (CVS). 
 
Presymptomatic Diagnosis  
Diagnosis of a genetic condition before the appearance of symptoms.  
 
Retinoblastoma 
Occurs in early childhood and affects about 1 child in 20,000. The tumor develops from 
the immature retina - the part of the eye responsible for detecting light and color. There 
are both hereditary and non-hereditary forms of retinoblastoma. IN the hereditary form, 
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multiple tumors are found in both eyes, while in the non-hereditary form only one eye is 
effected and by only one tumor. 
 
 
Sickle Cell Anemia  
An hereditary, chronic form of hemolytic anemia characterized by breakdown of the red 
blood cells; red blood cells undergo a reversible alteration in shape when the oxygen 
tension of the plasma falls slightly and a sickle-like shape forms.  
  
Single-Gene Disorder  
Hereditary disorder caused by a mutant allele of a single gene (e.g., Duchenne muscular 
dystrophy, retinoblastoma, sickle cell disease).  
 
Stem cell  
Undifferentiated, primitive cells in the bone marrow that have the ability both to 
multiply and to differentiate into specific blood cells.  
 
Syndrome  
A recognizable pattern or group of multiple signs, symptoms or malformations that 
characterize a particular condition; syndromes are thought to arise from a common 
origin and result from more than one developmental error during fetal growth.  
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Tay-Sachs disease  
A fatal degenerative disease of the nervous system due to a deficiency of hexosamidase 
A, causing mental deficiency, paralysis, mental deterioration, and blindness; found 
primarily but not exclusively among Ashkenazi Jews. Autosomal recessive.  
 
 
GLOSSARY OF GENETIC TERMS ADAPTED AND CITED FROM: 
 
 
Genetics Education Center  
Reprinted with permission from: 
University of Kansas Medical Center Copyright © 1995-2003.  
Debra Collins, M.S. CGC, Genetic Counselor, dcollins@kumc.edu
http://www.kumc.edu/gec/glossnew.html 
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Funded by the National Institutes of Health, the Human Resource and Service 
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Psychejam.Com 
http://www.psychejam.com/altzheimer's.htm 
 
Glossary: Health on the Net Foundation 
http://www.hon.ch/Library/Theme/Allergy/Glossary/hla.html 
 
Primary Care and Family Health 
GENETIC DISEASE BRANCH  
Glossary of Selected Medical Terms 
http://www.dhs.cahwnet.gov/pcfh/gdb/html/GDB/screening.htm 
 
National Digestive Diseases Information Clearinghouse (NDDIC) 
A service of the National Institute of Diabetes and Kidney Diseases (NIDDK) 
http://digestive.niddk.nih.gov/ddiseases/pubs/hemochromatosis/index.htm 
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WebbMD 
http://aolsvc.health.webmd.aol.com/content/article/7/1680_53571.htm?SRC=aolKW=he
mophilia 
 
Genes and Disease 
http://www.ncbi.nlm.nih.gov/books/bv.fcgi?call=bv.View.ShowSection&rid=gnd.sectio
n.129 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 140
 
APPENDIX B 
 
TEXAS A&M INSTITUTIONAL REVIEW BOARD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 141
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 142
 
APPENDIX C 
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Interview Guide for Physicians, Nurses and Social Workers 
In-Depth Interviews 
Qualitative Phase 
 
Beliefs and Training Needs of Health Professionals 
Regarding Genetics and Public Health: 
Developing and Validating a Survey Instrument 
 
 
Question Type 
 
Wording 
Opening statement The objective of this study is to learn about health professionals’ 
beliefs, knowledge, training needs and perceptions of their roles 
concerning the relationship between new genetic developments (the 
“new genetics”) and public health. We are also interested in learning 
how providers perceive the potential impact of the “new genetics” on 
their daily practice, and their views on prevention of genetic-related 
health problems. 
 
Opening question Please tell us your name and a little bit about what you do and where 
you do it. 
 Probe:  name of institution/place of employment 
  Specialization 
  Practice 
  How long in current practice? 
 Impact on Public Health 
Introductory Given the recent discoveries and developments in the study of 
human genetics, how do you see these developments affecting public 
health?  
 
Key Do you have any concerns regarding this impact of genetic 
discoveries on public health? Probe: 
Any concerns that media attention to genetic issues may 
raise public anxiety and increase the demand for genetic  
services? 
 Impact on Provider’s Own Practice 
Key How do you see this “new genetics” (as these developments have 
been recently termed) affecting what you do here on a regular basis?  
Probe: 
Workload implications 
Training 
Key What are some of the barriers that professionals like you may 
encounter when dealing with genetic-related issues (either prevention 
or treatment/management)? 
Key 
 
 
 
When you see a client who you suspect may need to deal with 
genetic issues, what do you do? 
                Probe:  Counsel 
                             Refer 
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Question Type 
 
Wording 
Key IF REFER:  Who would/do you refer this person to? 
                Probe:  Genetic Services 
                             Specialists in the field of concern (e.g.,  
                             ophthalmology; oncology) 
                             Colleagues for second opinion 
Key As far as you know, are there any genetic services available to you 
for consult and/or for referral of patients? 
  
Training Needs 
Transition This “new genetics” is producing quite a bit of new information.  How 
do you see yourself handling this new information? 
               Probe:  CEU 
                            Additional Training 
                            Referring/Not dealing with it 
Key Have you attended any continuing education courses in genetics? 
              Probe:  CEU 
                           Conference presentations 
Key Do you feel you need additional training in genetics? If so – in which 
aspects would they need additional training? 
  
Key For you, what would be the best way to receive additional training?  
 Probe: CEUs 
  Teleconferences 
  Professional Conferences 
  Workshops 
  In-services 
  Academic Detailing 
  
Prevention 
Transition When I say “prevention of genetic-related health problems”, what 
comes to mind? 
 
Key As you see it, who will have the responsibility to focus on prevention 
of genetic-related health problems? 
 Probe:  Do they perceive their role as preventive or  
  curative/management? 
  Is prevention the job of the health educator / nurse? 
Should genetic testing be patient- or physician-
driven? 
 
Key In your opinion, what are the most effective strategies for prevention 
of genetic-related health problems? 
 
Key What is the role of family planning, in the prevention of genetic-
related health problems? 
 Un-Addressed Concerns 
Ending Are there any concerns or other issues that are important for us to 
address in a survey of health care providers, concerning this topic? 
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Interview Guide for Geneticists 
In-Depth Interviews 
Qualitative Phase 
 
Beliefs and Training Needs of Health Professionals 
Regarding Genetics and Public Health: 
Developing and Validating a Survey Instrument 
 
 
Question Type 
 
Wording 
Opening statement The objective of this study is to learn about health professionals’ 
beliefs, knowledge, training needs and perceptions of their roles 
concerning the relationship between new genetic developments (the 
“new genetics”) and public health. We are also interested in learning 
how providers perceive the potential impact of the “new genetics” on 
their daily practice, and their views on prevention of genetic-related 
health problems. 
Opening question Please tell us your name and a little bit about what you do and where 
you do it. 
 Probe:  name of institution/place of employment 
  Specialization 
  Practice 
  How long in current practice? 
  
Impact on Public Health 
Introductory Given the recent discoveries and developments in the study of 
human genetics, how do you see these developments affecting public 
health?  
 
Key Do you have any concerns regarding this impact of genetic 
discoveries on public health? Probe: 
Any concerns that media attention to genetic issues may raise public 
anxiety and increase the demand for genetic services? 
 
  
Impact on Provider’s Own Practice 
Key How do you see this “new genetics” (as these developments have 
been recently termed) affecting what primary care providers do in 
their practice? 
Workload implications 
Training 
Key What are some of the barriers that primary care professionals may 
encounter when dealing with genetic-related issues (either prevention 
or treatment/management)? 
  
Training Needs 
Key Do you feel PCPs need additional training in genetics? If so – in 
which aspects would they need additional training? 
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Question Type 
 
Wording 
  
  
Key What would be the best way for PCPs to receive additional training?  
 Probe: CEUs 
  Teleconferences 
  Professional Conferences 
  Workshops 
  In-services 
  Academic Detailing 
 
  
Prevention 
Transition When I say “prevention of genetic-related health problems”, what 
comes to mind? 
 
Key As you see it, who will have the responsibility to focus on prevention 
of genetic-related health problems? 
 Probe:  Do they perceive their role as preventive or  
  curative/management? 
  Is prevention the job of the health educator / nurse? 
Should genetic testing be patient- or physician-driven? 
 
Key In your opinion, what are the most effective strategies for prevention 
of genetic-related health problems? 
 
Key What is the role of family planning, in the prevention of genetic-
related health problems? 
 
  
Un-Addressed Concerns 
Ending Are there any concerns or other issues that are important for us to 
address in a survey of health care providers, concerning this topic? 
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Interview Guide for Health Educators  
In-Depth Interviews 
Qualitative Phase 
 
Beliefs and Training Needs of Health Professionals 
Regarding Genetics and Public Health:  
Developing and Validating a Survey Instrument 
 
Question Type 
 
Wording 
Opening statement The objective of this study is to learn about health professionals’ 
beliefs, knowledge, training needs and perceptions of their roles 
concerning the relationship between new genetic developments (the 
“new genetics”) and public health. We are also interested in learning 
how providers perceive the potential impact of the “new genetics” on 
their daily practice, and their views on prevention of genetic-related 
health problems. 
 
Opening question Please tell us your name and a little bit about what you do and where 
you do it. 
 Probe:  name of institution/place of employment 
  Area of Specialization 
  How long in current position? 
 
  
Impact on Public Health 
Introductory Given the recent discoveries and developments in the study of human 
genetics, with the discovery of several disease-causing genes for 
instance, how do you see these developments affecting public health?  
 
Key Do you have any concerns regarding this impact of genetic discoveries 
on public health?  
 
Key How do you see this “new genetics” (as these developments have been 
recently termed) affecting your work as a health educator? 
 
 How do you see the role of health education in the future, considering 
these new genetic developments we’re seeing? 
Key What are some of the barriers that professionals like you may 
encounter when dealing with genetic-related issues (either prevention 
or treatment/management)? 
 
  
Training Needs 
Transition 
 
 
 
 
 
 
This “new genetics” is producing quite a bit of new information.  How do 
you see yourself handling this new information? 
             Probe:  CEU 
                          Additional Training 
                          Referring/Not dealing with it 
 
 148
 
Question Type 
 
Wording 
Key Have you attended any continuing education courses on genetics? 
             Probe:  CEU 
                          Conference presentations 
Key 
 
Do you feel you need additional training in genetics? If so – in which 
aspects would you like to have additional training? 
 
  
Key What would be the best way to receive additional training?  
 Probe: CEUs 
  Teleconferences 
  Professional Conferences 
  Workshops 
  In-services 
  Academic Detailing 
 
  
Prevention 
Transition When I say “prevention of genetic-related health problems”, what 
comes to mind? 
 
Key As you see it, who will have the responsibility to focus on prevention of 
genetic-related health problems? 
  
Key In your opinion, what are the most effective strategies for prevention of 
genetic-related health problems? 
 
Key What is the role of family planning, in the prevention of genetic-related 
health problems? 
 
  
Un-Addressed Concerns 
Ending Are there any concerns or other issues that are important for us to 
address in a survey of health educators, concerning this topic? 
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TEXAS A&M UNIVERSITY 
College of Education and Human Development 
Department of Health & Kinesiology                                                             
 
[Date] 
                            
Dear Dr. 
 
I need your help with my dissertation research! 
 
If you would take a few minutes to fill out this short but very important survey, it would 
be very appreciated.  Results of the survey will be used to examine the factors that 
influence the likelihood of physicians incorporating genomic medicine into their primary 
care practice.  This survey does not intend to measure knowledge about genetic 
medicine. 
 
“I think it is basically going to 
change therapeutics, and it is 
going to change diagnosis….it 
won’t take away everything that 
we are doing now, but it is going 
to change what we are doing 
now.” 
             (Texas physician, 2001) 
 
 
You are being invited to participate in this survey (along with 50 peers) because your 
name was recommended by an acquaintance.  All surveys will be number coded but 
your answers are completely confidential.  Only statistical information from aggregated 
data will be used for reporting. 
                                                                                   
If you have any questions about the survey, feel free to call me or write me at the 
address below.  If you prefer, the completed survey can be faxed back. 
 
Thank you very much for helping with this important study. 
 
Sincerely, 
 
Sandra Suther, M.A.                                                                               
Texas A&M University 
Department of Health & Kinesiology 
4243 Tamu 
College Station, TX 77843-4243  
Phone: 210-573-0618 
Fax:  979-696-0618 
ssuther@tamu.edu 
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TEXAS A&M UNIVERSITY 
College of Education and Human Development 
Department of Health & Kinesiology 
 
Informed Consent for Pilot Study Survey Participants 
Genomic Medicine in Primary Care:  Texas Physicians’ Adoption of an Innovation 
 
DATE, 2003 
I have been invited to participate in a pilot study of the views that primary care physicians in Texas have of 
genomic medicine.  
Sandra Suther is conducting this study.  Presently, she is a doctoral student in health education and health 
promotion in the Department of Health and Kinesiology, College of Education and Human Development, at Texas 
A&M University. One of her main research interests is public health genetics.  This study is part of her dissertation 
research. 
The recent completion of the first draft of the human genome sequence is generating concerns among health 
communities world-wide regarding the role of “genomic medicine” in primary care. While many primary care 
physicians already incorporate genetic screening into their routine services, it has been predicted that new genetic tests 
and genetic treatments stemming from the Human Genome Project will become a routine component of primary care. 
The proposed study intends to investigate primary care physicians’ perceptions of genomic medicine that may 
influence the adoption of this innovation into their primary care practice.  
 I am being invited to participate in this survey (along with 50 peers) because my name was recommended by 
an acquaintance. 
 My participation in this study entails answering this survey and returning it to Sandra Suther, in the enclosed 
self-addressed stamped envelope by ___________________.   My participation is voluntary and I am not obligated to 
answer any of the questions posed in the questionnaire. As there is little information on this subject, however, my 
input will represent a valuable contribution to the study of primary care professionals’ views of genomic medicine. 
 Some of the risks, discomforts and inconveniences that are reasonable to expect in this study are feeling that 
I haven’t thought through some of the questions enough to provide answers, or feeling as if I don’t have the “right” 
answer. On the other hand, some of the benefits that may reasonably be expected from participating in this study are: 
the opportunity to state my point-of-view on the subject and to reflect on my role as a health professional. 
 I understand that every effort will be made to keep all information confidential. My decision whether to 
participate will not affect my future relations with Texas A&M University, in any way.  I understand I am under no 
obligation to participate in the study.  I may withdraw from the study at any time, if I wish to.   
 This research study has been reviewed and approved by the Institutional Review Board – Human Subjects in 
Research, Texas A&M University. If I have any research-related problems or questions regarding subjects’ rights I 
may contact the  
Texas A & M Institutional Review Board through Dr. Michael W. Buckley, IRB Coordinator, Office of Vice President 
for Research at (979) 845-8585, mwbuckley@tamu.edu.   
 If, at any time, I have any questions about this study or further information I would like to add, I may 
contact Sandra Suther at the phone number or e-mail address below, or her advisor, Dr. Patricia Goodson at (979) 845-
1756 or pgoodson@hlkn.tamu.edu. 
 I also understand that by filling out the survey and returning it by mail, I’m agreeing to participate in this 
study, and I may keep this copy of the informed consent. 
 
PRINCIPAL INVESTIGATOR:________________________ 
Sandra Suther, M.A.  
Department of Health and Kinesiology 
Texas A&M University  
4243 TAMU 
College Station TX 77843-4243 
Phone: 979-696-0618 
E-mail: ssuther@neo.tamu.edu
_________________________________________ 
SURVEY PARTICIPANT 
 
_____________ 
DATE 
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“I think it is basically going to 
change therapeutics, and it is 
going to change diagnosis….it 
won’t take away everything that 
we are doing now, but it is going 
to change what we are doing 
now.” 
             (Texas physician, 2001) 
                                                     
 
TEXAS A&M UNIVERSITY 
College of Education and Human Development 
Department of Health & Kinesiology 
 
[Date] 
 
Dear Dr.  
 
I need your help with my dissertation research! 
 
If you would take a few minutes to fill out this short but very important survey, it would 
be greatly appreciated.  Results of the survey will be used to examine the factors that 
influence the likelihood of physicians incorporating genomic medicine into their primary 
care practice.  This survey does not intend to measure knowledge about genetic 
medicine. 
 
 
 
Your name was randomly selected from the Texas State Board of Medical Practitioners.  
All surveys will be number coded but your answers are completely confidential.  Only 
statistical information from aggregated data will be used for reporting. 
                                                                                   
If you have any questions about the survey, feel free to call me or write me at the 
address below.  If you prefer, the completed survey can be faxed back. 
 
Thank you very much for helping with this important study. 
 
Sincerely, 
 
Sandra Suther, M.A.                                                                               
Texas A&M University 
Department of Health & Kinesiology 
4243 Tamu 
College Station, TX 77843-4243  
Phone: 210-573-0618 
Fax:  979-696-0618 
ssuther@tamu.edu 
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TEXAS A&M UNIVERSITY 
College of Education and Human Development 
Department of Health & Kinesiology 
 
Informed Consent for Survey Participants 
Genomic Medicine in Primary Care:  Texas Physicians’ Adoption of an Innovation 
 
April, 2003 
I have been invited to participate in a study of the views that primary care physicians in Texas have of 
genomic medicine.  Sandra Suther is conducting this study.  Presently, she is a doctoral student in health education 
and health promotion in the Department of Health and Kinesiology, College of Education and Human Development, at 
Texas A&M University. One of her main research interests is public health genetics.  This study is part of her 
dissertation research. 
The recent completion of the first draft of the human genome sequence is generating concerns among health 
communities world-wide regarding the role of “genomic medicine” in primary care. While many primary care 
physicians already incorporate genetic screening into their routine services, it has been predicted that new genetic tests 
and genetic treatments stemming from the Human Genome Project will become a routine component of primary care. 
The proposed study intends to investigate primary care physicians’ perceptions of genomic medicine that may 
influence the adoption of this innovation into their primary care practice.  
 I am being invited to participate in this survey (along with 1,350 peers) because my name was randomly 
chosen from the Texas State Board of Medical Examiners’ directory of practitioners. 
 My participation in this study entails answering this survey and returning it to Sandra Suther, in the enclosed 
self-addressed stamped envelope by ___________________.   My participation is voluntary and I am not obligated to 
answer any of the questions posed in the questionnaire. As there is little information on this subject, however, my 
input will represent a valuable contribution to the study of primary care professionals’ views of genomic medicine. 
 Some of the risks, discomforts and inconveniences that are reasonable to expect in this study are feeling that 
I haven’t thought through some of the questions enough to provide answers, or feeling as if I don’t have the “right” 
answer. On the other hand, some of the benefits that may reasonably be expected from participating in this study are: 
the opportunity to state my point-of-view on the subject and to reflect on my role as a health professional. 
 I understand that every effort will be made to keep all information confidential.  Even though surveys 
received a number-code so demographic differences between respondents and non-respondents can be assessed, these 
codes will only be available to the principal investigator, and will be kept in a locked file in her office until surveys are 
returned. After that, the list will be destroyed.  
 My decision whether to participate will not affect my future relations with Texas A&M University, in any 
way.  I understand I am under no obligation to participate in the study.  I may withdraw from the study at any time, if I 
wish to.   
 This research study has been reviewed and approved by the Institutional Review Board – Human Subjects in 
Research, Texas A&M University. If I have any research-related problems or questions regarding subjects’ rights I 
may contact the  
Texas A & M Institutional Review Board through Dr. Michael W. Buckley, IRB Coordinator, Office of Vice President 
for Research at (979) 845-8585, mwbuckley@tamu.edu.   
 If, at any time, I have any questions about this study or further information I would like to add, I may 
contact Sandra Suther at the phone number or e-mail address below, or her advisor, Dr. Patricia Goodson at (979) 845-
1756 or  pgoodson@hlkn.tamu.edu. 
 I also understand that by filling out the survey and returning it by mail, I’m agreeing to participate in this 
study, and I may keep this copy of the informed consent. 
 
PRINCIPAL INVESTIGATOR:________________________ 
Sandra Suther, M.A.  
Department of Health and Kinesiology 
Texas A&M University  
4243 TAMU 
College Station TX 77843-4243 
Phone: 979-696-0618 
E-mail: ssuther@neo.tamu.edu
 
_________________________________________ 
SURVEY PARTICIPANT 
 
_____________ 
DATE 
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Sandra Gayle Suther was born in Houston, Texas, on November 7, 1950, the 
daughter of Beatrice and Ausber E. Reynolds.  She and her husband George have two 
children, Natalie and Christopher.  After receiving a Bachelor of Arts degree in 
anthropology from The University of Texas at San Antonio in 1996, she enrolled in the 
Master of Arts program in anthropology to pursue her interest in medical anthropology.  
Employed as an ophthalmic technician during those years, she assisted in numerous 
medical/surgical missions in Mexico, which inspired her interest in culture and 
medicine.  She also spent three years doing field research in the Rio Grande Valley of 
Texas and Mexico for a SPRANS funded Maternal and Child Health Genetics Project.  
Upon graduation in 2000 she applied and was accepted into the Health Education 
graduate program at Texas A&M University.  While pursuing her doctoral degree, she 
had the opportunity to be involved with two research projects; a program evaluation of 
abstinence-only education programs in Texas, funded by the Texas Department of 
Health and a qualitative study of barriers to the provision of genetic services in primary 
care, funded by a grant from Texas A&M University.  She was awarded outstanding 
graduate student 2002-2003. 
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